<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80246</article-id><article-id pub-id-type="doi">10.7554/eLife.80246</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Antibiotic-induced accumulation of lipid II synergizes with antimicrobial fatty acids to eradicate bacterial populations</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-281038"><name><surname>Sidders</surname><given-names>Ashelyn E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8700-261X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280737"><name><surname>Kedziora</surname><given-names>Katarzyna M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-308660"><name><surname>Arts</surname><given-names>Melina</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-308661"><name><surname>Daniel</surname><given-names>Jan-Martin</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-308659"><name><surname>de Benedetti</surname><given-names>Stefania</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281039"><name><surname>Beam</surname><given-names>Jenna E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281040"><name><surname>Bui</surname><given-names>Duyen T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281041"><name><surname>Parsons</surname><given-names>Joshua B</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-199798"><name><surname>Schneider</surname><given-names>Tanja</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7269-4716</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279134"><name><surname>Rowe</surname><given-names>Sarah E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8955-359X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-279640"><name><surname>Conlon</surname><given-names>Brian P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2155-8375</contrib-id><email>bconlon@med.unc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill</institution></institution-wrap><addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Department of Genetics, University of North Carolina at Chapel Hill</institution></institution-wrap><addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Bioinformatics and Analytics Research Collaborative, University of North Carolina at Chapel Hill</institution></institution-wrap><addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041nas322</institution-id><institution>Institute for Pharmaceutical Microbiology, University of Bonn</institution></institution-wrap><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Division of Infectious Diseases, Duke University</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Marsico Lung Institute, University of North Carolina at Chapel Hill</institution></institution-wrap><addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Helaine</surname><given-names>Sophie</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Garrett</surname><given-names>Wendy S</given-names></name><role>Senior Editor</role><aff><institution>Harvard T.H. Chan School of Public Health</institution><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>06</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e80246</elocation-id><history><date date-type="received" iso-8601-date="2022-05-13"><day>13</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-05"><day>05</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-05-03"><day>03</day><month>05</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.05.03.490474"/></event></pub-history><permissions><copyright-statement>© 2023, Sidders et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Sidders et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80246-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-80246-figures-v2.pdf"/><abstract><p>Antibiotic tolerance and antibiotic resistance are the two major obstacles to the efficient and reliable treatment of bacterial infections. Identifying antibiotic adjuvants that sensitize resistant and tolerant bacteria to antibiotic killing may lead to the development of superior treatments with improved outcomes. Vancomycin, a lipid II inhibitor, is a frontline antibiotic for treating methicillin-resistant <italic>Staphylococcus aureus</italic> and other Gram-positive bacterial infections. However, vancomycin use has led to the increasing prevalence of bacterial strains with reduced susceptibility to vancomycin. Here, we show that unsaturated fatty acids act as potent vancomycin adjuvants to rapidly kill a range of Gram-positive bacteria, including vancomycin-tolerant and resistant populations. The synergistic bactericidal activity relies on the accumulation of membrane-bound cell wall intermediates that generate large fluid patches in the membrane leading to protein delocalization, aberrant septal formation, and loss of membrane integrity. Our findings provide a natural therapeutic option that enhances vancomycin activity against difficult-to-treat pathogens, and the underlying mechanism may be further exploited to develop antimicrobials that target recalcitrant infection.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd><italic>Staphylococcus aureus</italic></kwd><kwd>antibiotic</kwd><kwd>adjuvant</kwd><kwd>lipid II</kwd><kwd>cell wall biosynthesis</kwd><kwd>unsaturated fatty acids</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI137273</award-id><principal-award-recipient><name><surname>Conlon</surname><given-names>Brian P</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000861</institution-id><institution>Burroughs Wellcome Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Conlon</surname><given-names>Brian P</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000897</institution-id><institution>Cystic Fibrosis Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Conlon</surname><given-names>Brian P</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>398967434 – TRR261</award-id><principal-award-recipient><name><surname>Schneider</surname><given-names>Tanja</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000923</institution-id><institution>Silicon Valley Community Foundation</institution></institution-wrap></funding-source><award-id>2020–225716</award-id><principal-award-recipient><name><surname>Kedziora</surname><given-names>Katarzyna M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Palmitoleic acid not only potentiates vancomycin killing of Gram-positive bacteria, but the insertion of palmitoleic acid into the membrane leads to the unexpected accumulation of membrane-bound cell wall precursors, representing a novel mechanism of action for unsaturated fatty acids.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The 1950s were the golden age of antibiotic discovery with nearly half of our current arsenal of therapeutics discovered in a single decade (<xref ref-type="bibr" rid="bib2">Aminov, 2010</xref>). Vancomycin, derived from the word ‘vanquish,’ is one of the key discoveries of the golden age that has maintained clinical utility through the present day (<xref ref-type="bibr" rid="bib77">Rubinstein and Keynan, 2014</xref>). Vancomycin is a glycopeptide antibiotic that targets lipid II, an essential membrane-bound building block of the cell wall. Lipid II is synthesized in the cytoplasm and subsequently flipped to the outer leaflet of the cell membrane where it is incorporated into the mature peptidoglycan layer (<xref ref-type="bibr" rid="bib72">Rajagopal and Walker, 2017</xref>). Vancomycin binds to the terminal <sc>d</sc>-Ala-<sc>d</sc>-Ala residues of lipid II, sterically hindering its incorporation into the growing peptidoglycan layer, resulting in cessation of cell wall biosynthesis and subsequent accumulation of lipid II on the cell surface (<xref ref-type="bibr" rid="bib26">Grein et al., 2019</xref>; <xref ref-type="bibr" rid="bib69">Qiao et al., 2017</xref>). Since lipid II is highly conserved across bacterial species, it is often referred to as the ‘Achilles’ heel’ of cell wall biosynthesis and an ideal antibacterial target (<xref ref-type="bibr" rid="bib65">Müller et al., 2017</xref>).</p><p>Resistance to vancomycin is a growing problem that limits its utility against some infections (<xref ref-type="bibr" rid="bib16">De Oliveira et al., 2020</xref>). Resistance is mediated by the acquisition of an inducible <italic>van</italic> cassette encoding seven proteins that generate an alternative lipid II peptide terminus, <sc>d</sc>-Ala-<sc>d</sc>-Lac, that significantly reduces vancomycin binding (<xref ref-type="bibr" rid="bib16">De Oliveira et al., 2020</xref>). About 1 in 3 hospital-associated <italic>Enterococcus faecalis</italic> isolates are vancomycin-resistant. Such high-level vancomycin resistance is also possible in <italic>Staphylococcus aureus</italic>, although it is rare with only 14 cases identified to date in the United States (<xref ref-type="bibr" rid="bib57">McGuinness et al., 2017</xref>). However, vancomycin-intermediate <italic>S. aureus</italic> (VISA) strains, which exhibit reduced susceptibility to vancomycin through a variety of non-specific adaptations including a thickening of the cell wall, are increasingly common (<xref ref-type="bibr" rid="bib57">McGuinness et al., 2017</xref>). It is also important to acknowledge that vancomycin treatment frequently fails in the absence of resistance, and this failure is often attributed to antibiotic tolerance (<xref ref-type="bibr" rid="bib98">Van den Bergh et al., 2017</xref>). Antibiotic tolerance is the ability of a bacterial population, or a sub-population of tolerant cells called persisters, to survive high concentrations of bactericidal antibiotics and regrow when antibiotic pressure is removed, leading to re-establishment of the infection (<xref ref-type="bibr" rid="bib31">Hill et al., 2021</xref>). Additionally, antibiotic tolerance can lead to the evolution of resistance (<xref ref-type="bibr" rid="bib98">Van den Bergh et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Levin-Reisman et al., 2017</xref>). Thus, to improve patient outcome, we need to develop strategies that can target both antibiotic resistant and antibiotic tolerant populations.</p><p>Despite renewed interest in funding antibiotic development, the pipeline is sparse, with few new drugs reaching the market (<xref ref-type="bibr" rid="bib49">Lewis, 2020</xref>). Developing feasible strategies to revitalize our current arsenal of antibiotics, such as the use of antibiotic adjuvants, which enhance the efficacy of an already approved therapeutic, are highly desirable (<xref ref-type="bibr" rid="bib24">Gray and Wenzel, 2020a</xref>). Cell membrane-acting agents (CMAAs) have frequently been overlooked in drug discovery, as they often lack selectivity for bacterial membranes and display promiscuous activity toward mammalian cells (<xref ref-type="bibr" rid="bib33">Hurdle et al., 2011</xref>). However, the clinical success and specificity of approved membraneactive antibiotics such as daptomycin, polymyxin, and second-generation glycopeptides have highlighted their utility (<xref ref-type="bibr" rid="bib49">Lewis, 2020</xref>). Additionally, there are several membrane-targeting antibiotic candidates in pre-clinical development (<xref ref-type="bibr" rid="bib49">Lewis, 2020</xref>; <xref ref-type="bibr" rid="bib56">Martin et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Kim et al., 2019</xref>). Our group and others have also previously identified CMAAs that significantly improved the efficacy of aminoglycosides against antibiotic-tolerant <italic>S. aureus</italic> (<xref ref-type="bibr" rid="bib70">Radlinski et al., 2017</xref>; <xref ref-type="bibr" rid="bib71">Radlinski et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Kim et al., 2018</xref>; <xref ref-type="bibr" rid="bib89">Song et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Beavers et al., 2022</xref>).</p><p>Second-generation glycopeptides, known as lipoglycopeptides, are more potent variants of vancomycin that can bypass vancomycin resistance. Their improved activity is attributed to the lipophilic side chain of lipoglycopeptides that anchor into and disturb the bacterial membrane (<xref ref-type="bibr" rid="bib65">Müller et al., 2017</xref>). Thus, we were interested in examining the ability of various CMAAs to potentiate vancomycin activity. Here, we identify two antimicrobial fatty acids that are potent vancomycin adjuvants against tolerant and resistant Gram-positive bacteria. Furthermore, we describe the mechanism by which these fatty acids and vancomycin work together to compromise the bacterial cell membrane, leading to rapid cell death.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Unsaturated fatty acids potentiate vancomycin killing of <italic>S. aureus</italic></title><p>We have previously shown that rhamnolipids, a biosurfactant produced by <italic>Pseudomonas aeruginosa</italic>, synergizes with aminoglycosides, highlighting the potential of targeting the membrane to enhance antibiotic efficacy against <italic>S. aureus</italic> (<xref ref-type="bibr" rid="bib71">Radlinski et al., 2019</xref>). We reasoned that CMAAs may also enhance the killing activity of glycopeptides since second-generation glycopeptides have a lipophilic tail and display potent activity (<xref ref-type="bibr" rid="bib7">Blaskovich et al., 2018</xref>). We investigated the capacity of seven CMAAs to enhance the bactericidal activity of vancomycin (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Sublethal concentrations of each CMAA were established experimentally or from our previously published work (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>; <xref ref-type="bibr" rid="bib71">Radlinski et al., 2019</xref>). Vancomycin and CMAAs both have potent bactericidal activity against low-density bacterial populations (10<sup>5</sup>–10<sup>6</sup> colony forming unit [CFU]/ml), but bactericidal activity wanes as population density increases (<xref ref-type="bibr" rid="bib46">LaPlante and Rybak, 2004</xref>; <xref ref-type="bibr" rid="bib39">Kollef, 2007</xref>; <xref ref-type="bibr" rid="bib67">Parsons et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Loffredo et al., 2021</xref>). We examined the bactericidal activity of vancomycin and CMAAs alone or in combination against <italic>S. aureus</italic> population of 10<sup>8</sup> CFU/ml, similar to the cell density of an abscess or infected wound (<xref ref-type="bibr" rid="bib68">Pletzer and Hancock, 2018</xref>; <xref ref-type="bibr" rid="bib40">König et al., 1998</xref>; <xref ref-type="bibr" rid="bib96">Udekwu et al., 2009</xref>). At this density, vancomycin monotherapy resulted in an approximately 2-log reduction in bacterial abundance but did not eradicate the population (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Benzyl alcohol, a general membrane fluidizer known to lack antimicrobial activity alone, did not display synergy with vancomycin (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib67">Parsons et al., 2012</xref>; <xref ref-type="bibr" rid="bib64">Müller et al., 2016</xref>). Lauric acid, a saturated fatty acid, and its monoglyceride derivative, glycerol monolaurate, which synergizes with other antibiotics such as aminoglycosides, did not synergize with vancomycin (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib71">Radlinski et al., 2019</xref>; <xref ref-type="bibr" rid="bib13">Churchward et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Hess et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Fischer, 2020</xref>). Adarotene, a synthetic retinoid that also potentiates aminoglycosides, did not potentiate vancomycin killing (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib36">Kim et al., 2018</xref>). In contrast, rhamnolipids improved vancomycin killing (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), while palmitoleic acid and linoleic acid, two host-produced unsaturated fatty acids (UFAs), were the most potent adjuvants tested, resulting in a 6-log decrease in viable bacteria after 6 hr (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Palmitoleic and linoleic acid are both <italic>cis</italic> UFAs, a 16-carbon monounsaturated and 18-carbon polyunsaturated fatty acid, respectively (<xref ref-type="bibr" rid="bib67">Parsons et al., 2012</xref>). Both UFAs have well-established antimicrobial activity and contribute to innate immunity in human nasal secretions, sebaceous glands of the skin, and breast milk (<xref ref-type="bibr" rid="bib104">Wille and Kydonieus, 2003</xref>; <xref ref-type="bibr" rid="bib17">Do et al., 2008</xref>). At the bacterial density and concentration examined here, neither palmitoleic acid nor linoleic acid had any activity against <italic>S. aureus</italic> in the absence of vancomycin (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). However, when these UFAs were combined with vancomycin, we observed over 99% killing of both methicillin-sensitive <italic>S. aureus</italic> (MSSA) and methicillin-resistant <italic>S. aureus</italic> (MRSA) populations after only 30 min (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>). Importantly, the dual treatment eradicated the antibiotic-tolerant persister populations as indicated by the absence of a characteristic persister plateau (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>; <xref ref-type="bibr" rid="bib85">Sidders et al., 2021</xref>). Additionally, we evaluated if dual treatment could bypass chemically induced tolerance using carbonyl cyanide m-chlorophenyl hydrazone (CCCP) to disrupt proton motive force or arsenate (AsKO) to deplete ATP (<xref ref-type="bibr" rid="bib15">Conlon et al., 2016</xref>). While reduced ATP levels typically protect from antibiotics, we found that palmitoleic acid still potentiated vancomycin killing of <italic>S. aureus</italic> in a low energy, tolerant state (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). These data indicate that palmitoleic acid is a potent adjuvant against tolerant and susceptible <italic>S. aureus</italic> populations.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Palmitoleic acid rapidly potentiates vancomycin killing of <italic>S. aureus</italic>.</title><p>(<bold>A</bold>) <italic>S. aureus</italic> HG003 cultures were grown to exponential phase and subsequently treated with CMAAs ± vancomycin (20 μg/ml, 20 X MIC of HG003). Colony forming units (CFUs) were enumerated after 6 hr. CMAAs tested include rhamnolipids (30 μg/ml), palmitoleic acid (11 μg/ml), linoleic acid (12 μg/ml), glycerol monolaurate (30 μg/ml), lauric acid (30 μg/ml), adarotene (3.2 μg/ml), and benzyl alcohol (40 mM). The statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparison test comparing dual treated conditions to vancomycin alone. Unless indicated, comparisons were not significant. Data represent n=6 biologically independent replicates. (<bold>B</bold>) Methicillin-sensitive <italic>S. aureus</italic> (MSSA) strain HG003 (<bold>C</bold>) or community-acquired methicillin-resistant <italic>S. aureus</italic> (MRSA) strain LAC was challenged with DMSO (Ctrl), palmitoleic acid (11 μg/ml), vancomycin (20 μg/ml), orcombination therapy. CFU was enumerated at indicated time points. Data represent the mean values from n=6 biologically independent replicates ± SD. Statistical significance was determined using a two-way ANOVA with Dunnett’s multiple comparison test on the final time point evaluated (<bold>B and C</bold>). Comparisons made between the control and experimental conditions are indicated in the associated line color. ** and **** denote p&lt;0.01 and p&lt;0.0001, respectively. VAN, vancomycin; RL, rhamnolipids; PA, palmitoleic acid; LA, linoleic acid; GML, glycerol monolaurate; Ad, adarotene; BA, benzyl alcohol.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig1">Figure 1A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Structures of CMAAs evaluated for synergy with vancomycin.</title><p>(<bold>A</bold>) Rhamnolipid, a biosurfactant produced by <italic>Pseudomonas aeruginosa;</italic> (<bold>B</bold>) palmitoleic acid, a monounsaturated fatty acid; (<bold>C</bold>) linoleic acid, a polyunsaturated fatty acid; (<bold>D</bold>) glycerol monolaurate, a monoglyceride; (<bold>E</bold>) lauric acid, a saturated fatty acid; (<bold>F</bold>) adarotene, a synthetic retinoid; (<bold>G</bold>) benzyl alcohol, a general membrane fluidizer.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Identification of sublethal concentration of UFAs.</title><p>HG003 was grown to exponential phase prior to challenge with 5, 11, 15, or 30 μg/ml of (<bold>A</bold>) PA alone, (<bold>B</bold>) PA +VAN (20 μg/ml), (<bold>C</bold>) LA alone, or (<bold>D</bold>) LA + VAN. An aliquot of cells was removed at the indicated time point, washed, and plated for colony forming unit (CFU). Data represent the mean values from n=3 biologically independent replicates ± SD. PA, palmitoleic acid; LA, linoleic acid; VAN, vancomycin.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A–D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig1-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Palmitoleic acid potentiates vancomycin killing against chemically induced tolerance.</title><p>HG003 was grown to exponential phase and treated for 30 min with (<bold>A</bold>) Arsenate (AsKO, 5 mM), or (<bold>B</bold>) carbonyl cyanide m-chlorophenyl hydrazone (CCCP; 1 μM) prior to the addition of antibiotics. After 2 hr, an aliquot of cells was removed, washed, and plated to enumerate survivors. Data represent the mean values from n=6 biologically independent replicates ± SD. PA, palmitoleic acid; VAN, vancomycin.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A–B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig1-figsupp3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig1-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Antibiotic synergy is mediated by the accumulation of membrane-bound cell wall intermediates</title><p>Because palmitoleic acid exhibited the greatest synergy with vancomycin, we next evaluated whether palmitoleic acid synergizes with other cell wall inhibitors. Antibiotics that target cell wall biosynthesis can be divided into three categories based on their target: early cytoplasmic steps (fosfomycin), membrane-bound steps (vancomycin and bacitracin), and assembly/incorporation steps of peptidoglycan (β-lactams; <xref ref-type="bibr" rid="bib72">Rajagopal and Walker, 2017</xref>). The latter two categories make up the majority of clinically relevant antibiotics that target the cell wall (<xref ref-type="bibr" rid="bib72">Rajagopal and Walker, 2017</xref>). To gain insight into the mechanism of synergy within the context of the peptidoglycan biosynthesis pathway, we evaluated representative cell wall-acting antibiotics from each category in combination with palmitoleic acid (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Fosfomycin inhibits the cytosolic steps of peptidoglycan biosynthesis by targeting and irreversibly inhibiting enzymes MurA-B (<xref ref-type="bibr" rid="bib19">Falagas et al., 2016</xref>). Fosfomycin did not exhibit synergy with palmitoleic acid (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). β-lactam antibiotics target penicillin-binding proteins (PBPs) which are responsible for incorporating lipid II into the mature peptidoglycan and the cross-linking of peptidoglycan (<xref ref-type="bibr" rid="bib83">Schneider and Sahl, 2010</xref>). Oxacillin inhibits PBP2 while nafcillin inhibits all four PBPs in <italic>S. aureus</italic>. Neither β-lactams exhibit synergy with palmitoleic acid (<xref ref-type="fig" rid="fig2">Figure 2C–D</xref>). These data indicate that UFAs do not synergize with antibiotics that target the early cytoplasmic steps or the assembly/incorporation steps of peptidoglycan synthesis.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Accumulation of bactoprenol is necessary for palmitoleic acid potentiation of antibiotics.</title><p>(<bold>A</bold>) Schematic depicting cell wall biosynthesis, with each arrow in between intermediates indicating an enzymatic step. The cell wall is composed mainly of peptidoglycan, a polymer consisting of N-acetyl-glucosamine (NAG) and N-acetylmuramic acid (NAM) residues, the latter affixed with a short pentapeptide. NAM is attached to a lipid anchor known as bactoprenol and further modified to generate lipid II. Lipid II is flipped to the outer leaflet of the membrane and incorporated into the growing peptidoglycan layer. Bactoprenol is recycled and reused in a cyclic process. The targets inhibited by the antibiotics tested in (<bold>B–F</bold>) are indicated in red. Schematic created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender.com</ext-link>. (<bold>B–F</bold>) Survival of HG003 challenged with indicated antibiotic monotherapy (black circles) or the antibiotic combined with PA (11 μg/ml, green square). Colony forming units (CFUs) were enumerated at indicated time points. Antibiotics tested include (<bold>B</bold>): fosfomycin (250 μg/ml)±PA, (<bold>C</bold>): the PBP2 inhibitor, oxacillin (OX, 5 X MIC, 5 μg/ml)±PA, (<bold>D</bold>): the PBP1-4 inhibitor, nafcillin (NAF, 5 X MIC, 2.5 μg/ml)±PA, (<bold>E</bold>): bacitracin (BAC, 250 μg/ml)±PA, and (<bold>F</bold>): tarocin A1 (8 μg/ml)±PA. Data represent the mean values from n=6 biologically independent replicates ± SD. Statistical analysis was evaluated at the end point by a two-tailed unpaired Student’s <italic>t</italic>-test with a 95% CI; conditions with significance are indicated on the graph, ****p&lt;0.0001, otherwise comparisons were not significant.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig2">Figure 2B–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig2-v2.tif"/></fig><p>Vancomycin binds to the <sc>d</sc>-Ala-<sc>d</sc>-Ala moiety of lipid II and sterically hinders its incorporation into mature peptidoglycan; this indirectly causes an accumulation of lipid II on the cell membrane (<xref ref-type="bibr" rid="bib69">Qiao et al., 2017</xref>). With this in mind, we wanted to determine if synergy with palmitoleic acid requires the accumulation of membrane-bound precursors. Bacitracin inhibits the recycling of the essential bactoprenol lipid carrier (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="bibr" rid="bib91">Stone and Strominger, 1971</xref>). Interestingly, while bacitracin monotherapy displayed negligible activity, the addition of palmitoleic acid led to drastic potentiation of bacitracin killing similar to vancomycin (<xref ref-type="fig" rid="fig2">Figures 2E</xref> and <xref ref-type="fig" rid="fig1">1B–C</xref>). Sequestration of the limited pool of bactoprenol carrier lipids by vancomycin and bacitracin reduces wall teichoic acid (WTA) biosynthesis by redirecting any remaining bactoprenol toward peptidoglycan biosynthesis (<xref ref-type="bibr" rid="bib87">Singh et al., 2017</xref>). Because WTAs have been found to protect <italic>S. aureus</italic> from the antimicrobial activity of UFAs (<xref ref-type="bibr" rid="bib67">Parsons et al., 2012</xref>), we assessed whether WTA inhibition contributed to the mechanism of synergy using the WTA inhibitor tarocin A1 (<xref ref-type="bibr" rid="bib47">Lee et al., 2016</xref>). We found that inhibition of WTA biosynthesis alone does not synergize with palmitoleic acid and likely does not contribute to the potentiation of vancomycin or bacitracin (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Taken together, these results suggest that palmitoleic acid relies on antibiotic induced accumulation of bactoprenol bound intermediates.</p><p>We next validated that lipid-bound intermediates were accumulating by analyzing the membrane fraction of cell-wall precursors via high-performance liquid chromatography (HPLC). As expected, both vancomycin alone and in combination with palmitoleic acid led to the accumulation of lipid II, although dual treatment led to less accumulation of lipid II compared to vancomycin alone (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Interestingly, in the presence of palmitoleic acid, we found an unexpected peak that eluted earlier than both lipid II and lipid I (<xref ref-type="fig" rid="fig3">Figure 3A–B</xref>). Upon further inspection with a different method to improve separation of the lipid intermediate, we identified that the peak aligned with our bactoprenol standard suggesting our unknown peak represented an accumulation of bactoprenol (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Additionally, we find that even palmitoleic acid alone leads to the accumulation of bactoprenol, although a lower quantity comparative to dual treatment, indicating a novel mechanism of action for UFAs (<xref ref-type="fig" rid="fig3">Figure 3A–B</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Treatment with palmitoleic acid induces accumulation of bactoprenol.</title><p>(<bold>A</bold>) <italic>S. aureus</italic> was grown to exponential phase and treated with DMSO (Control), PA monotherapy (11 μg/ml), VAN monotherapy (20 μg/ml), or PA +VAN combination therapy for 30 min. The membrane fraction was extracted and run on a C4 column. The question mark indicates an unknown peak. Additional peaks in VAN monotherapy may be glycinylated versions of lipid II. (<bold>B</bold>) High-performance liquid chromatography (HPLC) of a combined lipid I and lipid II, as well as a bactoprenol standard run alongside samples in A. (<bold>C</bold>) Samples run in A were subsequently run with a different method to yield better separation of bactoprenol and lipid I. PA +VAN samples align with the bactoprenol standard. Right Y-axis refers to PA +VAN samples due to lower concentrations of sample after sequential use in two different columns. Chromatograms are examples of n=3 biological replicates. PA, palmitoleic acid; VAN, vancomycin.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig3">Figure 3A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig3-v2.tif"/></fig><p>Previous studies have determined that the accumulation of lipid II is saturated after 30 min of vancomycin treatment (<xref ref-type="bibr" rid="bib69">Qiao et al., 2017</xref>). We speculate that the rapid killing seen with dual treatment in that time frame relies on maximizing lipid II and bactoprenol on the cell surface (<xref ref-type="bibr" rid="bib69">Qiao et al., 2017</xref>; <xref ref-type="bibr" rid="bib12">Chugunov et al., 2013</xref>). If palmitoleic acid prevents bactoprenol recycling, it is likely that the pool of lipid II available becomes significantly smaller making it easier for vancomycin to saturate its lethal target at the septum. This may explain why dual treated cells had less accumulation of lipid II than vancomycin alone (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p></sec><sec id="s2-3"><title>Large regions of increased fluidity are generated by combining palmitoleic acid and vancomycin</title><p>Recent studies show that the bactoprenol-bound precursors, such as lipid II, alter the surrounding phospholipid bilayer (<xref ref-type="bibr" rid="bib12">Chugunov et al., 2013</xref>). To accommodate the long hydrocarbon tail of these molecules, a long-lived hydrophobic and fluid microdomain are generated in the membrane, also known as regions of increased fluidity (RIFs; <xref ref-type="bibr" rid="bib64">Müller et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Chugunov et al., 2013</xref>). The presence of RIFs in the membrane also serves an essential role in the spatial organization of complex machinery that is involved in cell envelope biosynthesis. However, antibiotics that target lipid II utilize the unique characteristics of RIFs as a ‘landing terrain’ that distinguishes their target within a ‘sea’ of other lipids (<xref ref-type="bibr" rid="bib12">Chugunov et al., 2013</xref>). Similar to the bulky hydrophobic nature of bactoprenol, the <italic>cis</italic> unsaturation in palmitoleic acid causes a ‘kink’ in its hydrocarbon tail which also favors a membrane environment with increased fluidity and hydrophobicity (<xref ref-type="bibr" rid="bib59">Mingeot-Leclercq and Décout, 2016</xref>). Furthermore, palmitoleic acid is likely to preferentially insert at the septum where lipid II and bactoprenol are localized in RIFs. We hypothesized that cell death occurs by the induction of large RIF formation due to the combined accumulation of palmitoleic acid, bactoprenol, and lipid II, resulting in a disruption of membrane organization.</p><p>To investigate the effects of combination or monotherapy on <italic>S. aureus</italic> membrane fluidity and RIF organization, we utilized high-resolution fluorescence microscopy. The fluorescent lipophilic dyes nile red and DiI-C12 both insert into the membrane and preferentially accumulate and fluoresce brighter in areas of the phospholipid bilayer with increased fluidity (<xref ref-type="bibr" rid="bib64">Müller et al., 2016</xref>; <xref ref-type="bibr" rid="bib102">Wenzel et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Kucherak et al., 2010</xref>). Unlike <italic>Bacillus subtilis,</italic> which is large enough to visualize RIF organization in untreated cells using DiI-C12 (<xref ref-type="bibr" rid="bib92">Strahl et al., 2014</xref>), the small cell size (~0.5–1.0 μm) of <italic>S. aureus</italic> impedes RIF visualization (<xref ref-type="bibr" rid="bib25">Gray and Wenzel, 2020b</xref>). RIFs in <italic>S. aureus</italic> only become clearly visible when cells are treated with membrane-active agents that cause the formation of large RIFs, as seen previously with rhodomyrtone and daptomycin (<xref ref-type="bibr" rid="bib25">Gray and Wenzel, 2020b</xref>; <xref ref-type="bibr" rid="bib78">Saeloh et al., 2018</xref>).</p><p>Consistent with previous studies, the untreated <italic>S. aureus</italic> cells exhibit smooth, consistent fluorescence across the membrane using either nile red or DiI-C12 (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>; <xref ref-type="bibr" rid="bib78">Saeloh et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Monteiro et al., 2015</xref>). Similarly, vancomycin monotherapy illustrated smooth membrane staining with either dye, although DiI-C12 fluorescence was brighter compared to control cells suggesting some overall increased fluidity in vancomycin treated cells (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). Palmitoleic acid also increased overall Dil-C12 fluorescence indicating some increased fluidity in the presence of the fatty acid alone (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). However, when cells were treated with both palmitoleic acid and vancomycin, large foci were easily observable using either nile red or Dil-C12, indicating the formation of large RIFs during dual treatment (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). Even at sublethal concentrations of vancomycin, where no cell death occurs, RIFs are still obvious in dual treated cells, though less pronounced (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Importantly, nile red staining remained uniform in cells treated with a CMAA that did not potentiate vancomycin (glycerol monolaurate) and in cells treated with palmitoleic acid combined with oxacillin (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). These data indicate that regardless of concentration, only cells treated with vancomycin and palmitoleic acid generate detectable RIFs.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Dual treatment generates distinct fluid membrane patches.</title><p><italic>S. aureus</italic> (HG003) treated with DMSO, PA (11 μg/ml), VAN (20 μg/ml), PA +VAN (10 μg/ml), or PA +VAN (20 μg/ml) for (<bold>A and B</bold>) 10 min or (<bold>C</bold>) 30 min. (<bold>A and C</bold>) HG003 was stained with fluorescent BODIPY-labeled VAN and nile red for 5 min. (<bold>B</bold>) Regions of increased fluidity (RIFs) in HG003 were visualized by DiI-C12. Cells were fixed prior to imaging on an agarose pad. Images are representative of the population. Scale bar, 1 μm. (<bold>D–F</bold>) Bioinformatic analysis of all cells treated for 30 min and imaged, n=2 or 3 separate biological replicates. (<bold>D</bold>) The number of nile red foci in each cell was quantified for each treatment group and represented as a percent of the total population. (<bold>E</bold>) Scatter plot of cell size of each cell in the indicated treatment group. The black line represents the median. Statistical significance was determined by one-way ANOVA with Dunnett’s multiple comparisons test, and all conditions had a p&lt;0.0001, ****, compared to the control. (<bold>F</bold>) The cell cycle was determined for each cell in a given treatment group and illustrated as a percent of the total population; phase 1 (P1), phase 2 (P2), and phase 3 (P3).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig4">Figure 4D–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Sublethal concentrations of vancomycin with palmitoleic acid result in regions of increased fluidity.</title><p>(<bold>A</bold>) HG003 was grown to exponential phase prior to the addition of palmitoleic acid (11 μg/ml) combined with vancomycin at 1, 5, or 10 μg/ml. After 10 min, antibiotics were removed, and cells were stained with nile red and fluorescently labeled vancomycin for 5 min. Cells were fixed prior to imaging on an agarose pad. Images are representative of the population. Scale bar, 1 μm. (<bold>B</bold>) In one replicate, an aliquot of cells was removed prior to fixation, washed, and plated for colony forming unit (CFU) to evaluate whether the combination was sublethal in the images taken.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Regions of increased fluidity are not microscopically visible in the absence of synergy.</title><p>HG003 was grown to exponential phase prior to challenge with DMSO (control), palmitoleic acid (11 μg/ml), vancomycin (10 μg/ml), glycerol monolaurate (30 μg/ml), oxacillin (5 μg/ml), or a combination of these compounds as indicated in the figure. After 10 min, antibiotics were removed, and cells were stained with nile red and fluorescently labeled vancomycin for 5 min. Cells were fixed prior to imaging on an agarose pad. Images are representative of the population. Scale bar, 1 μm. PA, palmitoleic acid; VAN, vancomycin; GML, glycerol monolaurate; OX, oxacillin.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Image analysis of cells treated for 10 min.</title><p>Bioinformatic analysis of the total population imaged after 10 min of antibiotic treatment. Representative images can be found in <xref ref-type="fig" rid="fig4">Figure 4A</xref>. (<bold>A</bold>) Number of nile red labeled foci per cell in each treatment group was quantified and represented as a percent of the total population. (<bold>B</bold>) Scatter plot of cell volume per cell in each treatment group overall (i.e. P1–P3). Analysis of cell volume is further broken down by (<bold>C</bold>) cells only in P1, (<bold>D</bold>) cells only in P2, or (<bold>E</bold>) cells only in P3. Black line represents the median. Statistical significance was determined by one-way ANOVA with Dunnett’s multiple comparisons test comparing each condition to the control. n.s., *, **** denotes, not significant, p&lt;0.05, and p&lt;0.0001, respectively. (<bold>F</bold>) The cell cycle was determined for each cell in each treatment group and represented as a percent of the total population. (<bold>G</bold>) Schematic of the cell cycle and representative examples of cells classified in each phase. VAN, vancomycin; PA, palmitoleic acid; P1, phase 1; P2, phase 2; P3, phase 3.</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig4-figsupp3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Dual treatment leads to a significant reduction in cell size compared to control cells regardless of cell cycle phase.</title><p>Bioinformatic analysis of cell volume based on cell cycle phase after 30 min of treatment. Representative images can be found in <xref ref-type="fig" rid="fig4">Figure 4C</xref>, and the overall cell volume of the population by treatment group can be found in <xref ref-type="fig" rid="fig4">Figure 4E</xref>. (<bold>A–C</bold>) Scatter plots of cell volume per cell in each treatment group broken down by (<bold>A</bold>) cells only in P1, (<bold>B</bold>) cells only in P2, or (<bold>C</bold>) cells only in P3. Black line represents the median. Statistical significance was determined by one-way ANOVA with Dunnett’s multiple comparisons test comparing each condition to the control. n.s., ***, **** denotes, not significant, p=0.0005, and p&lt;0.0001, respectively. For representative examples of cells in each phase see <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3G</xref>. VAN, vancomycin; PA, palmitoleic acid; P1, phase 1; P2, phase 2; P3, phase 3.</p><p><supplementary-material id="fig4s4sdata1"><label>Figure 4—figure supplement 4—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig4-figsupp4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig4-figsupp4-v2.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>PA-VAN synergy is unaffected by proteins associated with flotillin microdomains.</title><p>All <italic>S. aureus</italic> strains were grown to exponential phase prior to the indicated treatment. An aliquot of cells was removed at the indicated time points, washed, and plated for colony forming unit (CFU) to enumerate survivors. (<bold>A</bold>) HG003 was treated with DAP (10 μg/ml)±PA (11 μg/ml). (<bold>B–D</bold>) JE2 wild-type, JE2 <italic>floA::</italic>Tn, and JE2 <italic>crtM::</italic>Tn were treated with DMSO (ctrl), PA (11 μg/ml), VAN (20 μg/ml), or PA and VAN. (<bold>E</bold>) HG003 cultures were treated with ZA for 30 min prior to the addition of VAN (20 μg/ml)±PA (11 μg/ml). Data represents n=6 biologically independent replicates with error bars as SD. DAP, daptomycin; PA, palmitoleic acid; WT, wild-type; VAN, vancomycin; ZA, zaragozic acid.</p><p><supplementary-material id="fig4s5sdata1"><label>Figure 4—figure supplement 5—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5A–E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig4-figsupp5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig4-figsupp5-v2.tif"/></fig></fig-group><p>Additionally, the RIF phenotype visualized at 10 min (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) was not transient, and images taken after 30 min also displayed large foci only in dual treated conditions (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Furthermore, dual treatment resulted in nearly 50% of the cell population with at least one foci per cell at both 10 and 30 min (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A</xref>). Interestingly, although there was not a difference in cell size after 10 min overall, examining the cell volume by cell cycle indicated that while dual treated cells are similar in size to control cells when in phase 3, cells in phases 1 and 2 were significantly smaller (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3B–E</xref>). However, after 30 min, dual treated cells had a significant decrease in cell volume overall and in all cell cycle phases (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A–C</xref>), suggesting that cell shrinkage occurs after prolonged exposure. We also examined the distribution of the cell cycle in each treatment group and found that at either time point, dual treated conditions had a larger proportion of the population in phase 3 (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3F–G</xref>). Phase 3 is a short elongation step prior to an incredibly fast separation event (<xref ref-type="bibr" rid="bib61">Monteiro et al., 2015</xref>; <xref ref-type="bibr" rid="bib108">Zhou et al., 2015</xref>), and typically, only a small proportion of the cell population is found in phase 3, as observed in control and monotherapy treated cells (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3F</xref>). These results demonstrate that dual treatment leads to large RIFs, cell shrinkage, and disruption of the cell cycle.</p><p>Previous work has shown that daptomycin causes large RIF formation similar to the phenotype we see with vancomycin and palmitoleic acid (<xref ref-type="bibr" rid="bib64">Müller et al., 2016</xref>). Because daptomycin can already induce RIF formation and has potent bactericidal activity alone, we did not anticipate synergy with palmitoleic acid. Indeed, when tested, palmitoleic acid did not potentiate daptomycin killing of <italic>S. aureus</italic> (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5A</xref>). Additional studies have shown that in the absence of FloA or CrtM, fluid microdomains can be disturbed (<xref ref-type="bibr" rid="bib109">Zielińska et al., 2020</xref>; <xref ref-type="bibr" rid="bib22">García-Fernández et al., 2017</xref>). Using <italic>S. aureus</italic> strains from the Nebraska Transposon Mutant Library, we investigated whether <italic>floA</italic> or <italic>crtM</italic> mutants would abrogate our phenotype. Interestingly, neither disruption of <italic>floA</italic> nor <italic>crtM</italic> impacted synergy between vancomycin and palmitoleic acid and looked identical to the parental strain JE2 (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5B–D</xref>). We further confirmed that FloA was not involved by pre-treatment with zaragozic acid, a statin that has previously been shown to disrupt FloA rafts (<xref ref-type="bibr" rid="bib22">García-Fernández et al., 2017</xref>). Pre-treatment also did not diminish palmitoleic acid potentiation of vancomycin killing (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5E</xref>). Taken together, these data suggest that the induction of large RIFs induced by dual vancomycin-palmitoleic acid treatment is independent of factors responsible for natural, coordinated RIF formation in growing cells.</p></sec><sec id="s2-4"><title>Dual treatment increases membrane permeability without forming a pore</title><p>Palmitoleic acid has previously been reported to increase permeability, albeit at higher concentrations and at lower cell densities than examined here (<xref ref-type="bibr" rid="bib67">Parsons et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Miller et al., 1977</xref>; <xref ref-type="bibr" rid="bib100">Wang and Johnson, 1992</xref>). However, since we observed a reduction in cell volume (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3C–E</xref>, <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A–C</xref>), we wanted to evaluate whether permeability is altered at sublethal concentrations of palmitoleic acid that achieve synergy with vancomycin. We first determined if combination or monotherapy led to cellular content leakage by measuring ATP in the supernatant. While the control and vancomycin monotherapy had minimal ATP leakage, all groups that were treated with palmitoleic acid had more ATP in the supernatant after 10 min. Compared to palmitoleic acid monotherapy, the dual treatment groups had significantly more ATP loss (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Dual treatment causes ATP leakage but not pore formation.</title><p>(<bold>A</bold>) <italic>S. aureus</italic> grown to exponential phase was treated with the indicated compounds for 10 min prior to separating the supernatant from the pellet. ATP measurements were taken using a plate reader and normalized to colony forming unit (CFU). (<bold>B</bold>) <italic>S. aureus</italic> grown to exponential phase was loaded with 8 μM of SYTOX Green and aliquoted into a microtiter plate prior to treatment. Membrane permeability was measured (485/522 nm) on a plate reader every 2 min for 28 min. (<bold>A–B</bold>) Cells were challenged with DMSO (control), nisin (200 IU/ml), or PA (11 μg/ml)±VAN (1, 5, or 10 μg/ml) were added as indicated on the graph. Data represent the mean values from n=2 or 3 biologically independent replicates with three technical replicates each ± SD. Statistical significance was determined by one-way ANOVA with Dunnett’s multiple comparisons test comparing the means of the technical replicates of each condition to PA alone. n.s. and * denote, not significant and p&lt;0.0332, respectively.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig5">Figure 5A–B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig5-v2.tif"/></fig><p>We next evaluated whether leakage of cellular content was due to pore formation by using SYTOX Green which is a membrane-impermeable dye that intercalates into DNA (<xref ref-type="bibr" rid="bib76">Roth et al., 1997</xref>). Even though we observed significant ATP leakage after 10 min, the membranes in all treatment groups remained impermeable to SYTOX Green after 10 min except for our positive control, nisin (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). These data indicate that the outflow of cytoplasmic contents is not associated with pore formation (<xref ref-type="bibr" rid="bib18">Epand et al., 2016</xref>), as is the case with nisin (<xref ref-type="bibr" rid="bib103">Wiedemann et al., 2004</xref>), but instead is likely due to increases in localized fluidity that may disturb lipid packing of the membrane and allow the escape of small molecules. This is also supported by previous work which has shown that UFAs increase membrane fluidity (<xref ref-type="bibr" rid="bib9">Boudjemaa et al., 2018</xref>). However, while increased permeability may be a contributing factor, it is unlikely to be the main cause of cell death, as most CMAAs we tested (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) have been shown to also increase membrane permeability, yet they did not potentiate vancomycin killing (<xref ref-type="bibr" rid="bib71">Radlinski et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Kim et al., 2018</xref>; <xref ref-type="bibr" rid="bib13">Churchward et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Hess et al., 2014</xref>).</p></sec><sec id="s2-5"><title>Dual treated <italic>S. aureus</italic> display aberrant septal synthesis and membrane defects</title><p>To further visualize membrane aberrations in dual-treated cells, we performed transmission electron microscopy (TEM). We observed normal cellular structure and septal formation in control, palmitoleic acid, and vancomycin monotherapy conditions (<xref ref-type="fig" rid="fig6">Figure 6A–C and E–G</xref>). In contrast, cells treated with both palmitoleic acid and vancomycin exhibited deformed septa that were misshapen and lacking an electron-dense mid-line compared to control cells (<xref ref-type="fig" rid="fig6">Figure 6D and H</xref>; yellow arrow). The dual treated cells additionally had an electron transparent region at the septa much thicker than the other conditions imaged and no discernable cell membrane or intermediate layer at the septum. Moreover, as expected based on fluorescence microscopy results, the dual treated cells had membrane aberrations that varied in size amongst the population of cells imaged (<xref ref-type="fig" rid="fig6">Figure 6H</xref>, red arrow). Interestingly, these ultrastructural alterations of the cell membrane and septa parallel those reported for lipoglycopeptide treated <italic>S. aureus</italic> (<xref ref-type="bibr" rid="bib6">Belley et al., 2009</xref>). Palmitoleic acid did not potentiate oritavancin killing of <italic>S. aureus</italic>, a lipoglycopeptide, likely due to oritavancin being a potent bactericidal agent capable of inducing aberrant septal formation when used alone (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Dual treated cells display septal aberrations.</title><p>The ultrastructure of <italic>S. aureus</italic> cells treated for 30 min was visualized by TEM. (<bold>A–H</bold>)<italic>S. aureus</italic> HG003 grown to mid-exponential phase was treated with DMSO (<bold>A and E</bold>), 11 μg/ml PA (<bold>B and F</bold>), 20 μg/ml VAN, (<bold>C and G</bold>) and PA +VAN (<bold>D, H</bold>). (<bold>A–C and E–G</bold>) Micrographs of cells with a cross wall at mid-cell, while (<bold>D and H</bold>) show cells treated with PA +VAN have deformed septa (yellow arrows) and membrane invaginations (red arrows). Magnification of 50,000× with a 0.5 μm scale bar (<bold>A–D</bold>) or magnification of 150,000× with a 200 nm scale bar (<bold>E–H</bold>). (<bold>E</bold>) (1) Electron-dense midline of the septum, (2) electron-dense intermediate layer, located between the (3) cell membrane and the (4) cell wall. The white holes in the cytoplasm of imaged cells are artifacts that occur during sample preparation (<xref ref-type="bibr" rid="bib95">Tizro et al., 1897</xref>). PA, palmitoleic acid; VAN, vancomycin.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Lipoglycopeptides do not synergize with palmitoleic acid.</title><p>HG003 was grown to exponential phase prior to treatment with oritavancin (10 μg/ml)±palmitoleic acid (11 μg/ml). Aliquots of cells were taken at indicated time points, washed, and plated to enumerate survivors. Data represents n=3 biological replicates and error bars as SD. ORI, oritavancin; PA, palmitoleic acid.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig6-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig6-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Dual treatment delocalizes cell division and peptidoglycan biosynthesis machinery</title><p>Disruption of RIF organization by other antibiotics has been found to displace or delocalize membrane-bound proteins, such as those of cell division and peptidoglycan biosynthesis (<xref ref-type="bibr" rid="bib64">Müller et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Saeloh et al., 2018</xref>). The divisome of <italic>S. aureus</italic> is a multi-protein complex that forms a ring at the site of cell division (<xref ref-type="bibr" rid="bib53">Lund et al., 2018</xref>). Cell division requires the highly coordinated efforts of peptidoglycan biosynthesis, hydrolysis, and turgor pressure (<xref ref-type="bibr" rid="bib61">Monteiro et al., 2015</xref>; <xref ref-type="bibr" rid="bib62">Monteiro et al., 2018</xref>). EzrA is an essential divisome protein that acts as a scaffold and regulator for the proper formation of the division ring at the septum (<xref ref-type="bibr" rid="bib53">Lund et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Steele et al., 2011</xref>). To determine whether the septal defects visualized with TEM are caused by an improper localization of the divisome complex, we utilized an <italic>S. aureus</italic> strain with a chromosomal EzrA-GFP fusion (<xref ref-type="bibr" rid="bib79">Saraiva et al., 2020</xref>). We found that the control and vancomycin treated cells maintained EzrA fluorescence at the septum as a single ring at the center of the cell (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). In contrast, we observed two distinct phenotypes following dual treatment with palmitoleic acid and vancomycin: delocalization of EzrA throughout the cell or multiple distinct rings within a single cell (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Interestingly, we observed a small subpopulation of cells treated with palmitoleic acid monotherapy with delocalized EzrA (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). This is consistent with a previous study that suggested low concentrations of antimicrobial lipids, including palmitoleic acid, exert bacteriostatic activity as a result of momentary cell division defects prior to cell recovery (<xref ref-type="bibr" rid="bib13">Churchward et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Cartron et al., 2014</xref>). As controls, we evaluated whether a CMAA that did not potentiate vancomycin (glycerol monolaurate) and an antibiotic that lacked synergy with palmitoleic acid (oxacillin) maintained the septal placement of EzrA. As expected, glycerol monolaurate plus vancomycin and oxacillin plus palmitoleic acid had proper placement of cell division machinery (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Dual treatment with vancomycin and palmitoleic acid causes septal protein delocalization.</title><p>Localization of cell division and peptidoglycan biosynthesis machinery after 10 min. (<bold>A</bold>) HG003 with chromosomal <italic>ezrA-gfp</italic> was grown to exponential phase prior to treatment with DMSO (control), VAN (1, 5, or 10 μg/ml), PA (11 μg/ml), or PA +VAN at indicated concentrations in parentheses. (<bold>B</bold>) HG003 was grown to exponential phase and treated for a total of 10 min as indicated, and HADA (blue) was added after 5 min. The compounds and HADA dye were washed from the cells and stained with wheat germ agglutinin (WGA; green) for 5 min and then fixed. Gray arrows illustrated aberrant localization of peptidoglycan synthesis. (<bold>A–B</bold>) After treatment, cells were fixed prior to imaging on an agarose pad. Scale bars,1 μm. n=2 biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Protein delocalization is absent when <italic>S. aureus</italic> is treated compounds that lack synergy with palmitoleic acid or vancomycin.</title><p>Localization of cell division machinery after 10 min was monitored using HG003 with a chromosomal <italic>ezrA-gfp</italic>. Cells were grown to exponential phase prior to treatment with vancomycin (10 μg/ml), palmitoleic acid (11 μg/ml), glycerol monolaurate (30 μg/ml), oxacillin (5 μg/ml), or in combination with palmitoleic acid or vancomycin as indicated. After treatment, cells were fixed prior to imaging on an agarose pad. Images are representative of the population. Scale bar, 1 μm. PA, palmitoleic acid; VAN, vancomycin; GML, glycerol monolaurate; OX, oxacillin.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig7-figsupp1-v2.tif"/></fig></fig-group><p>Since peptidoglycan synthesis is directly linked to cell division, we next aimed to determine if dual treatment alters peptidoglycan synthesis using HADA, a fluorescent <sc>d</sc>-amino acid that is incorporated into the newly synthesized cell wall, and wheat germ agglutinin (WGA) that stains mature cell wall (<xref ref-type="bibr" rid="bib44">Kuru et al., 2015</xref>). After 10 min, the lower vancomycin monotherapy concentrations had yet to inhibit cell wall biosynthesis, but the highest concentration had shut down peptidoglycan biosynthesis in a majority of the cells in any given field, as expected (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, PA +VAN10). In all control or monotherapy groups, HADA was correctly located at the septa (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). In contrast, when palmitoleic acid was combined with lower vancomycin concentrations that allowed HADA incorporation, we saw aberrant peptidoglycan incorporation (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, gray arrows). Peptidoglycan biosynthesis is a highly regulated process that occurs at the site of cell division prior to rapid daughter cell separation (<xref ref-type="bibr" rid="bib62">Monteiro et al., 2018</xref>). In contrast, we observed that dual treated cells began to initiate peptidoglycan synthesis at additional division planes prior to daughter cell separation further indicating cell division or cytokinesis defects (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, gray arrows) (<xref ref-type="bibr" rid="bib73">Reichmann et al., 2019</xref>). Together, these data suggest that vancomycin in combination with palmitoleic acid promotes divisome and peptidoglycan biosynthesis delocalization, leading to lethal aberrant septa formation.</p></sec><sec id="s2-7"><title>Palmitoleic acid sensitizes antibiotic-resistant isolates to vancomycin killing</title><p>One strategy to reduce the rise in resistance while also sensitizing already resistant and tolerant populations is to utilize chemotherapies with multiple bacterial targets (<xref ref-type="bibr" rid="bib24">Gray and Wenzel, 2020a</xref>). Here, we have identified that combining palmitoleic acid and vancomycin targets multiple essential processes; thus, we next aimed to determine if dual treatment can re-sensitize resistant isolates to vancomycin. Despite the decreased susceptibility to vancomycin in characterized vancomycin-resistant <italic>S. aureus</italic> (VRSA) and VISA clinical isolates (with MICs of &gt;16 μg/ml and 4 μg/ml, respectively; <xref ref-type="bibr" rid="bib41">Kosowska-Shick et al., 2008</xref>), dual treatment resulted in similar killing kinetics to MSSA with 99.9% of the cells killed after only 30 min (<xref ref-type="fig" rid="fig8">Figure 8A–B</xref>). Additionally, palmitoleic acid potentiated vancomycin killing of other Gram-positive bacteria, including <italic>E. faecalis</italic>, <italic>B. subtilis</italic>, <italic>Enterococcus faecium</italic>, and <italic>Staphylococcus epidermidis</italic> (<xref ref-type="fig" rid="fig8">Figure 8C–G</xref>). Importantly, palmitoleic acid was able to potentiate vancomycin killing of vancomycin-resistant <italic>E. faecalis</italic> (<xref ref-type="fig" rid="fig8">Figure 8D</xref>). However, palmitoleic acid did not potentiate killing of the Gram-negative bacterial species <italic>Escherichia coli</italic> (<xref ref-type="fig" rid="fig8">Figure 8H</xref>)<italic>,</italic> likely due to the outer membrane. These data illustrate the potency of palmitoleic acid as a vancomycin adjuvant against various Gram-positive bacteria, including those exhibiting vancomycin resistance.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Palmitoleic acid re-sensitizes vancomycin resistant isolates.</title><p>(<bold>A</bold>) Vancomycin-intermediate <italic>S. aureus</italic> (VISA) strain SA770 (<xref ref-type="bibr" rid="bib41">Kosowska-Shick et al., 2008</xref>) and (<bold>B</bold>) vancomycin-resistant <italic>S. aureus</italic> (VRSA) strain VRS2 (<xref ref-type="bibr" rid="bib41">Kosowska-Shick et al., 2008</xref>) were grown to exponential phase prior challenge with DMSO (Ctrl), PA (11 μg/ml), VAN (20 μg/ml), or VAN + PA. At the indicated time points, an aliquot was removed and plated to enumerate survivors. PA potentiation of other Gram-positive bacteria was determined using (<bold>C</bold>) <italic>E. faecalis</italic>, (<bold>D</bold>) vancomycin-resistant <italic>E. faecalis</italic> (VRE), (<bold>E</bold>) <italic>E. faecium,</italic> (<bold>F</bold>) <italic>B. subtilis</italic>, (<bold>G</bold>) <italic>S. epidermidis</italic>, and Gram-negative bacterial species (<bold>H</bold>) <italic>E. coli</italic>. Strains were grown to exponential phase prior to challenge with concentrations of PA ± VAN indicated in <xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>. After 2 hr, an aliquot was removed and plated for colony forming unit (CFU) enumeration. Data represents n=6 or 3 biologically independent replicates with error bars as SD. Significance was evaluated using Student’s two-tailed unpaired <italic>t</italic>-test between VAN and VAN + PA conditions.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig8">Figure 8A–H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80246-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80246-fig8-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Although new therapeutics are in the pipeline, preservation and improvement of pre-existing therapies are important for combatting rising rates of antibiotic treatment failure and antibiotic resistance. Vancomycin is a gold-standard antimicrobial as it took nearly 40 years after its introduction to the clinic before the first resistant isolate appeared (<xref ref-type="bibr" rid="bib97">Uttley et al., 1988</xref>). Unfortunately, vancomycin resistance is becoming more and more prevalent, particularly amongst Enterococci, where over half of all <italic>E. faecium</italic> and one-third of <italic>E. faecalis</italic> isolates now exhibit vancomycin resistance (<xref ref-type="bibr" rid="bib16">De Oliveira et al., 2020</xref>). Additionally, under certain environmental conditions including high-bacterial density, vancomycin is poorly bactericidal, facilitating antibiotic tolerance, infection recurrence, long hospital stays, and prolonged courses of parenteral antibiotics (<xref ref-type="bibr" rid="bib46">LaPlante and Rybak, 2004</xref>; <xref ref-type="bibr" rid="bib39">Kollef, 2007</xref>; <xref ref-type="bibr" rid="bib51">Liu et al., 2020</xref>). Here, we have identified a vancomycin adjuvant, palmitoleic acid, that potentiates vancomycin killing against multiple Gram-positive bacteria. Importantly, palmitoleic acid increased the rate of killing of vancomycin at high-bacterial densities, killing over 99.9% of the bacterial populations of most isolates within 30 min, improving significant pitfalls of vancomycin monotherapy.</p><p>The research focused on the antimicrobial activity of UFAs dates back nearly a century due to their potency at high concentrations and their lack of toxicity to mammalian tissue (<xref ref-type="bibr" rid="bib38">Kodicek, 1945</xref>; <xref ref-type="bibr" rid="bib10">Burtenshaw, 1942</xref>; <xref ref-type="bibr" rid="bib34">Kabara et al., 1972</xref>; <xref ref-type="bibr" rid="bib45">Lamar, 1911</xref>). UFAs are found in nasal secretions and on the skin as an important natural protective barrier, in addition to being commonly found in our diet (<xref ref-type="bibr" rid="bib104">Wille and Kydonieus, 2003</xref>; <xref ref-type="bibr" rid="bib11">Cartron et al., 2014</xref>; <xref ref-type="bibr" rid="bib66">Neumann et al., 2015</xref>). Mice deficient in skin monounsaturated fatty acid production show increased susceptibility to <italic>S. aureus</italic> in a complicated skin and soft tissue infection model (<xref ref-type="bibr" rid="bib23">Georgel et al., 2005</xref>; <xref ref-type="bibr" rid="bib94">Takigawa et al., 2005</xref>). Despite immense interest in antimicrobial fatty acids over the decades, a concise mechanism of action ascribed to UFAs remains unclear. Some effects attributed to UFA antibacterial activity include disruption of signal transduction, membrane depolarization, disruption in energy production, inhibition of fatty acid synthesis, increased permeability, and membrane dissolution (<xref ref-type="bibr" rid="bib67">Parsons et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Miller et al., 1977</xref>; <xref ref-type="bibr" rid="bib100">Wang and Johnson, 1992</xref>; <xref ref-type="bibr" rid="bib43">Kuiack et al., 2020</xref>; <xref ref-type="bibr" rid="bib107">Zheng et al., 2005</xref>).</p><p>In this work, we have identified yet another effect elicited by UFAs, the putative accumulation of the lipid carrier, bactoprenol. Importantly, this effect was seen with sublethal concentrations of palmitoleic acid and is not a direct result of cell death. We speculate that palmitoleic acid insertion will likely localize at the septum where there is a higher concentration of fluid phospholipids that make an ideal landing terrain. The septal disruption caused by palmitoleic acid insertion likely impedes the recycling of bactoprenol and thus results in its accumulation. As palmitoleic acid does not kill bacteria at the concentrations examined here, it is likely that the cell can detoxify palmitoleic acid from the membrane and reverse bactoprenol accumulation. Moreover, individually, both vancomycin and palmitoleic acid induced accumulation of precursors were not sufficient to generate large RIFs easily detectable by microscopy. However, when applied together, the combination results in a dramatic accumulation of membrane-bound intermediates that leads to the rapid formation of large RIFs, septal disorganization, and cell death. Importantly, previous work with teixobactin has shown similar intrinsic synergy by targeting multiple lipid-bound intermediates of cell wall biosynthesis simultaneously (<xref ref-type="bibr" rid="bib50">Ling et al., 2015</xref>).</p><p>Delocalization of protein machinery is likely a downstream effect of the sequestration of membrane-bound intermediates, as these intermediates are not only simple building blocks of peptidoglycan. In fact, lipid II appears to be the molecular signal for fine-tuning cell envelope biosynthesis, including during cell division (<xref ref-type="bibr" rid="bib28">Hardt et al., 2017</xref>). Interfering with lipid II localization subsequently disrupts the highly coordinated cell wall biosynthesis and divisome machinery causing complex downstream effects that are irreparable (<xref ref-type="bibr" rid="bib26">Grein et al., 2019</xref>; <xref ref-type="bibr" rid="bib27">Grein et al., 2020</xref>). Indeed, we visualized protein delocalization in dual treated cells as defective septal formation in TEM, multiple EzrA rings, and misplaced peptidoglycan biosynthesis.</p><p>The capacity of CMAAs to sensitize vancomycin-resistant isolates is not without precedence. Interestingly, previous studies have reported that prolonged pre-treatment with antimicrobial peptides re-sensitized VRSA to vancomycin (<xref ref-type="bibr" rid="bib60">Mohamed et al., 2016</xref>; <xref ref-type="bibr" rid="bib84">Shurko et al., 2018</xref>). Here, we find that administration of palmitoleic acid simultaneously with vancomycin re-sensitizes resistant strains to vancomycin killing. The most common mechanism of vancomycin resistance is the maintenance of a plasmid containing the <italic>vanA</italic> operon. Sensing of vancomycin activates transcription of the <italic>vanA</italic> operon and generates an altered form of lipid II that has a terminal <sc>d</sc>-Ala-<sc>d</sc>-Lac on the stem peptide which cannot be bound by vancomycin (<xref ref-type="bibr" rid="bib57">McGuinness et al., 2017</xref>). It is possible that the rapid bactericidal activity of the combination leaves little time for VRSA or VRE isolates to induce the expression of the <italic>van</italic> genes in response to vancomycin. Alternatively, the rapid delocalization of protein machinery seen with EzrA after only 10 min may indicate that the signal cascade required to activate the <italic>van</italic> operon may be disrupted by the vancomycin-palmitoleic acid combination.</p><p>Because UFAs are already a natural protectant on the skin surface and have been shown to accelerate wound healing in a rat model when applied topically (<xref ref-type="bibr" rid="bib101">Weimann et al., 2018</xref>), palmitoleic acid could potentially be utilized as a topical therapeutic in conjunction with intravenous vancomycin for complicated skin and soft-tissue infections. Topical antibiotic ointments are desirable as they provide localized high concentrations without the risk of systemic toxicity. The leading over-the-counter topical ointment, Polysporin or Neosporin, contains high concentrations of bacitracin for acute skin infections (<xref ref-type="bibr" rid="bib4">Banerjee and Argáez, 2017</xref>). Unfortunately, resistance to bacitracin is widespread in Staphylococci and Enterococci diminishing its utility against these infections (<xref ref-type="bibr" rid="bib55">Manson et al., 2004</xref>; <xref ref-type="bibr" rid="bib106">Yoshida et al., 2011</xref>). Since we find that palmitoleic acid potentiates bacitracin killing, it is possible that the addition of palmitoleic acid to these common ointments could improve their efficacy. However additional work is needed to evaluate the potential therapeutic efficacy of palmitoleic acid as a topical ointment in vivo.</p><p>In summary, the findings presented here demonstrate a promising approach to enhancing approved therapeutics that bypasses the need to identify novel antimicrobial compounds. Focusing on antibiotic adjuvants that are naturally non-toxic to improve the efficacy of essential antibiotics can combat antimicrobial resistance and tolerance. While unraveling the mechanism of action of membrane targeting antimicrobials has consistently been challenging, we provide an important and more detailed piece of the puzzle on how targeting lipid II and the unexpected effects of palmitoleic acid on the membrane in general leads to potent synergy.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain and strain background (<italic>Staphylococcus aureus</italic>)</td><td align="left" valign="bottom">HG003; MSSA</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1128/IAI.00088-10">10.1128/IAI.00088-10</ext-link></td><td align="left" valign="bottom">BC1561</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>S. aureus</italic>)</td><td align="left" valign="bottom">LAC; CA-MRSA</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1073/pnas.0710217105">10.1073/pnas.0710217105</ext-link></td><td align="left" valign="bottom">BC1684</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>S. aureus</italic>)</td><td align="left" valign="bottom">JE2 wild-type</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1128/mBio.00537-12">10.1128/mBio.00537-12</ext-link>.</td><td align="left" valign="bottom">BC9</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>S. aureus</italic>)</td><td align="left" valign="bottom">JE2 <italic>floA::</italic>Tn</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1128/mBio.00537-12">10.1128/mBio.00537-12</ext-link>.</td><td align="left" valign="bottom">BC1758</td><td align="left" valign="bottom">SAUSA300_1533; From NTML, strain NE184</td></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>S. aureus</italic>)</td><td align="left" valign="bottom">JE2 <italic>crtM::</italic>Tn</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1128/mBio.00537-12">10.1128/mBio.00537-12</ext-link>.</td><td align="left" valign="bottom">BC440</td><td align="left" valign="bottom">SAUSA300_2499; From NTML, strain NE1444</td></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>S. aureus</italic>)</td><td align="left" valign="bottom">HG003 <italic>ezrA-gfp</italic></td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1038/nature25506">10.1038/nature25506</ext-link></td><td align="left" valign="bottom">BC1552</td><td align="left" valign="bottom"><italic>ezrA-gfp</italic> was transduced from ColpSGEzrA-GFP into HG003 background for this work</td></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>S. aureus</italic>)</td><td align="left" valign="bottom">VISA</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1128/AAC.01073-08">10.1128/AAC.01073-08</ext-link></td><td align="left" valign="bottom">SA770; BC1477</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>S. aureus</italic>)</td><td align="left" valign="bottom">VRSA</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1128/AAC.01073-08">10.1128/AAC.01073-08</ext-link></td><td align="left" valign="bottom">VRS2; BC1479</td><td align="left" valign="bottom">Vancomycin-resistant</td></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>Enterococcus faecalis</italic>)</td><td align="left" valign="bottom">VRE</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1128/iai.00425-15">10.1128/iai.00425- 15</ext-link></td><td align="left" valign="bottom">V583; BC231</td><td align="left" valign="bottom">Vancomycin-resistant</td></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>E. faecalis</italic>)</td><td align="left" valign="bottom">OG1</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">BC524</td><td align="left" valign="bottom">ATCC 47077</td></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>Enterococcus faecium</italic>)</td><td align="left" valign="bottom">Clinical isolate</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1038/s41564-021-00966-0">10.1038/s41564-021-00966-0</ext-link></td><td align="left" valign="bottom">BC1540</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>Bacillus subtilis</italic>)</td><td align="left" valign="bottom">BS49</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1371/journal.pgen.1006701">10.1371/journal.pgen.1006701</ext-link></td><td align="left" valign="bottom">BC209</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">MG1655</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">BC15</td><td align="left" valign="bottom">ATCC 47076</td></tr><tr><td align="left" valign="bottom">Strain and strain background (<italic>Staphylococcus epidermidis</italic>)</td><td align="left" valign="bottom">CSF41498</td><td align="left" valign="bottom">doi:<ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1128/jb.01946-14">10.1128/jb.0194 6-14</ext-link></td><td align="left" valign="bottom">BC17</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Rhamnolipids</td><td align="left" valign="bottom">AGAE Technologies</td><td align="left" valign="bottom">Cat#R90</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Palmitoleic acid</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat. #10009871</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Linoleic acid</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat. #90150</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Glycerol monolaurate</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat.#28170</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Lauric acid</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat.#10006626</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Adarotene</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.#SML2061</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Benzyl alcohol</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat.#A396500</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Vancomycin</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat.#AAJ6279003</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Fosfomycin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.#P5396</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Oxacillin</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat.#AC45544005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Nafcillin</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat.#AC46138001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Bacitracin</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat.#BP29501</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Tarocin A1</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.#SML1677</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Daptomycin</td><td align="left" valign="bottom">MedChem Express</td><td align="left" valign="bottom">Cat.#HY-B0108</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">zaragozic acid</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.#z2626</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">Oritavancin</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat.#24091</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">AsKO</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.#A6756</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound and drug</td><td align="left" valign="bottom">CCCP</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat.#25458</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">BODIPY-VAN</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat.#V34850</td><td align="left" valign="bottom">Fluorescently labeled vancomycin, labeling cell wall, <xref ref-type="fig" rid="fig4">Figure 4</xref></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Nile red</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.#72485</td><td align="left" valign="bottom">Cell membrane dye, <xref ref-type="fig" rid="fig4">Figure 4</xref></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DiI-C12</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat.#D383</td><td align="left" valign="bottom">RIF specific dye, <xref ref-type="fig" rid="fig4">Figure 4</xref></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">HADA</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat.#66475</td><td align="left" valign="bottom">Dye that stains new cell wall, <xref ref-type="fig" rid="fig7">Figure 7</xref></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">WGA-488</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat.#W11261</td><td align="left" valign="bottom">Dye that stains mature cell wall, <xref ref-type="fig" rid="fig7">Figure 7</xref></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Sytox green</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat.#S7020</td><td align="left" valign="bottom">Cell viability dye, <xref ref-type="fig" rid="fig5">Figure 5</xref></td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BacTiter-Glo Microbial Viability Kit</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat.#G8232</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithm</td><td align="left" valign="bottom">Graphpad Prism</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">Graphpad.com</ext-link></td><td align="left" valign="bottom">Prism 9</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithm</td><td align="left" valign="bottom">Biorender</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">Biorender.com</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software and algorithm</td><td align="left" valign="bottom">Metamorph 7.10</td><td align="left" valign="bottom">Molecular Devices</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Acquisition software</td></tr><tr><td align="left" valign="bottom">Software and algorithm</td><td align="left" valign="bottom">Autoquant</td><td align="left" valign="bottom">Media cybernetics</td><td align="left" valign="bottom">Version 3.1.3</td><td align="left" valign="bottom">Deconvolution software</td></tr><tr><td align="left" valign="bottom">Software and algorithm</td><td align="left" valign="bottom">FIJI</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">v1.53q</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Bacterial growth and conditions</title><p><italic>S. aureus</italic> strains HG003 (MSSA; <xref ref-type="bibr" rid="bib29">Herbert et al., 2010</xref>), HG003 <italic>ezrA-gfp,</italic> LAC (CA-MRSA; <xref ref-type="bibr" rid="bib35">Kennedy et al., 2008</xref>), JE2, JE2 <italic>floA::tn</italic>, JE2 <italic>crtM::tn</italic> (<xref ref-type="bibr" rid="bib20">Fey et al., 2013</xref><xref ref-type="bibr" rid="bib20">Fey et al., 2013</xref>), SA770 (VISA), and VRS2 (VRSA; <xref ref-type="bibr" rid="bib41">Kosowska-Shick et al., 2008</xref>); <italic>B. subtilis</italic> strain BS49 (<xref ref-type="bibr" rid="bib3">Anjuwon-Foster and Tamayo, 2017</xref>), <italic>E. coli</italic> strain MG1655 (<xref ref-type="bibr" rid="bib8">Blattner et al., 1997</xref>), and <italic>S. epidermidis</italic> strain CSF41498 (<xref ref-type="bibr" rid="bib14">Conlon et al., 2014</xref>) were routinely cultured in tryptic soy broth (TSB, Remel) at 37°C with 225 rpm shaking. <italic>E. faecalis</italic> strains OG1 and V583 (<xref ref-type="bibr" rid="bib54">Maharshak et al., 2015</xref>) and a clinical <italic>E. faecium</italic> isolate (<xref ref-type="bibr" rid="bib1">Aggarwala et al., 2021</xref>) were cultured in Brain Heart Infusion Broth (Oxoid) at 37°C with shaking (<italic>E. faecium</italic>) or statically (<italic>E. faecalis</italic> strains). The EzrA-GFP was transduced from the chromosome of ColpSGEzrA-GFP (<xref ref-type="bibr" rid="bib62">Monteiro et al., 2018</xref>) to HG003 by phage transduction using phage 80α as previously described (<xref ref-type="bibr" rid="bib81">Schneewind and Missiakas, 2014</xref>).</p></sec><sec id="s4-2"><title>In vitro antibiotic survival assays</title><p>Antibiotic survival assays were performed as previously described (<xref ref-type="bibr" rid="bib85">Sidders et al., 2021</xref>). Briefly, overnight cultures were diluted 1:1000 into fresh media and grown for 3–5 hr depending on the strain to yield a starting inoculum in late exponential phase (~2 × 10<sup>8</sup> CFU/ml). The time required after back diluting an overnight culture to reach the starting inoculum was determined by performing growth curves of each strain (data not shown). Concentrations of antibiotics used in survival assays can be found in the figure legends or source data. At the indicated time points, an aliquot of cells was washed twice with PBS, serially diluted, and plated on tryptic soy agar to enumerate CFU. For assays with CCCP, AsKO, and zaragozic acid, these compounds were added 30 min prior to antibiotic challenge. Statistical analysis is indicated in the figure legends.</p></sec><sec id="s4-3"><title>Membrane integrity assays</title><p>Membrane permeability was measured using the SYTOX Green (Invitrogen) as previously described (<xref ref-type="bibr" rid="bib105">Yasir et al., 2019</xref>). Briefly, measurements were carried out in a Synergy H1 (BioTek) plate reader equipped with 480 nm excitation and 522 nm emission filters. <italic>S. aureus</italic> HG003 was grown in TSB as described above. After reaching the desired starting CFU, cells were washed thrice with PBS + 10% TSB and resuspended. Cells were loaded with SYTOX Green for 15 min at room temperature in the dark. Subsequently, 100 μl of cells were added to each well of a black flat bottom 96-well polystyrene plate that was non-binding (Corning, 3991) to prevent the necessity of BSA being added. The final concentration of SYTOX Green was 8 μM. Compounds were added at concentrations indicated in the figure legend, and reads were taken every 2 min for 28 min while shaking.</p><p>ATP levels were evaluated using the BactiterGLO kit (Promega) per manufacturer’s specifications and normalized to CFU that was taken after 10 min of treatment.</p></sec><sec id="s4-4"><title>Accumulation of cell wall precursors</title><p><italic>S. aureus</italic> HG003 was grown to ~1 × 10<sup>8</sup> CFU/mL before being treated with vancomycin (10 µg/mL), palmitoleic acid (11 µg/mL), or the combination of both for 30 min. Cell numbers were documented after treatment, and cells were harvested at 8000 rpm for 10 min before being resuspended in 1× PBS. Lipids were extracted by addition of an equal volume of <italic>n</italic>-butanol-pyridine acetate (2:1 [v/v] pH 4.2), followed by vigorous vortexing and 3 min of centrifugation at 13,500 rpm using a microfuge to achieve phase separation, as previously described (<xref ref-type="bibr" rid="bib63">Müller et al., 2012</xref>). The lipid containing upper phase was collected, and extraction was repeated with the lower phase. Upper phases were combined, washed twice with cold water (pH 4.2), and fully dried by desiccation. Dried lipids were resuspended in <italic>n</italic>-butanol with adjustment of the resuspension volume according to the normalized cell number. Analysis of lipid content was achieved by thin layer chromatography developed in the solvent according to Rick (CHCl<sub>3</sub>:MeOH:H<sub>2</sub>O:NH<sub>4</sub>OH [88:48:10:1]) followed by PMA staining as described before (<xref ref-type="bibr" rid="bib75">Rick et al., 1998</xref>; <xref ref-type="bibr" rid="bib82">Schneider et al., 2004</xref>). Additionally, samples were subjected to HPLC.</p></sec><sec id="s4-5"><title>HPLC of cell wall precursors</title><p>HPLC was performed on an Agilent 1260 Infinity II System (Agilent Technologies, Santa Clara, CA, USA) equipped with a VWD detector. Separation of lipid II was achieved on a MultoHigh Bio 300 – C4 (4 × 125 mm, 5 µm) with a flow rate of 0.5 ml/min at 30°C, using a linear gradient of 3:1:1 (H<sub>2</sub>O:MeOH:IPA) for 3 min, which increased to 100% 0.5:1:1 (H<sub>2</sub>O:MeOH:IPA) in 35 min and was maintained for 5 min. Before the following run, the gradient was returned to 0% in 2 min and was retained for 5 min. Both solvent mixtures were buffered with 10 mM H<sub>3</sub>PO<sub>4</sub>.</p><p>Separation of bactoprenol and lipid I was achieved on an Agilent Poroshell 120 C18 column (3 × 150 mm, 2.7 µm) with a flow rate of 0.3 ml/min at 30°C using an isocratic gradient for 50 min of 4:1 (MeOH:IPA) buffered with 10 mM H3PO4.</p><p>The data was analyzed by comparing the peaks against standards of different purified cell wall precursors. Data analysis was performed using OpenLab CDS software version 2.6.</p></sec><sec id="s4-6"><title>Fluorescence microscopy</title><p>All imaging was performed using <italic>S. aureus</italic> HG003 grown as described above prior to challenge with compounds at concentrations and time points indicated in figure legends.</p><p>To evaluate morphological changes, 1 ml of culture was incubated for 5 min at 37°C with 5 μg/ml of nile red (Sigma) to stain the membrane, and the cell wall was labeled with 1 μg/ml of an equal mixture of vancomycin (Alfa Aesar) and a BODIPY FL conjugate of vancomycin (Invitrogen). Excess dye was removed by washing with TSB. To determine if membrane perturbations were RIFs, the lipophilic dye DiI-C12 (Invitrogen) was used as described (<xref ref-type="bibr" rid="bib102">Wenzel et al., 2018</xref>). Briefly, overnight cultures were diluted 1:1000 into fresh TSB containing 1% DMSO and 1 μg/ml DiI-C12. Cells were grown to ~2 × 10<sup>8</sup> CFU/ml and washed four times with pre-warmed TSB containing 1% DMSO. Cells were then treated for 10 min and washed to remove excess antibiotic and dye. Washes and incubation steps were performed in a warm room to maintain samples at 37°C for optimal DiI-C12 solubility. For visualization of divisome proteins, overnight cultures of HG003 <italic>ezrA-gfp</italic> were diluted 1:1000 into fresh TSB and grown to ~2 × 10<sup>8</sup> CFU/ml. Cells were then treated for 10 min prior to washing with TSB. To visualize peptidoglycan biosynthesis, 1 ml of culture was incubated with the fluorescent <sc>d</sc>-amino acid HADA (Tocris Bioscience) at a final concentration of 250 μM for 5 min. The cells were subsequently washed with TSB and incubated with WGA tagged with Alexa Fluor 488 (WGA-488, Invitrogen) at a final concentration of 2 μg/ml for 5 min; excess WGA-448 was removed by washing with TSB. Both incubation steps were carried out at 37°C with agitation.</p><p>After staining, <italic>S. aureus</italic> was fixed with 4% paraformaldehyde made fresh day of for 20 min at room temperature with agitation. Cells were then washed with PBS and resuspended in 1st/10th the starting volume. Samples were imaged within 24 hr of fixation by pipetting 2 μl of sample onto an agarose pad (made as previously described <xref ref-type="bibr" rid="bib88">Skinner et al., 2013</xref>) and mounted onto a #1.5 cover slip.</p><p>Image Z-stacks were acquired using an Olympus IX81 inverted microscope fitted with a Hamamatsu ORCA-Flash4.0 V3 camera, X-Cite XYLIS XT720L (385) illumination, 100×/1.4 Oil UPlan S Apo PSF objective lens, and Metamorph 7.10 acquisition software (Molecular Devices). Z spacing was 0.2 μm, and pixel size in XY was 0.064 μm. Our Z-stacks ranged in thickness from 2.6 to 4.0 μm. We acquired images for all channels at each Z position before moving to the next Z position. Nile red was imaged with 560/25 excitation and 607/36 emission filters. BODIPY-VAN, EzrA, and WGA-488 were imaged with 485/20 excitation and 525/30 emission filters. HADA was imaged with 387/11 excitation and 440/40 emission filters. DiI-C12 was imaged with 572/35 excitation and 632/60 emission filters. All images were acquired with the same exposure settings. No pixels had saturated intensities. Z-stacks were subsequently deconvolved using Autoquant software version 3.1.3 with default settings. All images in a figure were processed in FIJI and have the same display adjustments. A single Z-plane that was determined to be the middle cross-section of <italic>S. aureus</italic> cells in the field of view was used for representative images of nile red, VAN-FL, WGA-488, and DiI-C12. A max projection of all Z-stacks was used for the representative images of HADA and EzrA-GFP.</p></sec><sec id="s4-7"><title>Image analysis</title><p>Image analysis was performed using Python with scikit-image (0.18.2) image processing library (<xref ref-type="bibr" rid="bib99">van der Walt et al., 2014</xref>) and Fiji (v1.53q; <xref ref-type="bibr" rid="bib80">Schindelin et al., 2012</xref>). The full analysis code is available on <ext-link ext-link-type="uri" xlink:href="https://github.com/fjorka/bacteria_pa_van_analysis">Github</ext-link> (copy archived at <xref ref-type="bibr" rid="bib86">Sidders et al., 2023</xref>), while all raw imaging data and key processed steps were deposited in <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.7753640">Zenodo</ext-link> repository.</p><p>For quantification of bacterial cell features (volume, phase, and foci number), a middle cross-section from confocal z-stacks was used. This plane was selected automatically by finding the frame with maximum cell area from thresholded (Otsu) images of the cell wall (BODIPY-VAN). Detection of cells was performed in the membrane channel (Nile Red) using cellpose segmentation algorithm (<xref ref-type="bibr" rid="bib93">Stringer et al., 2021</xref>). Total number of detected cells (all conditions) &gt;32 k. Volume of cells was calculated based on the major and minor axis length of segmented cells as described previously (<xref ref-type="bibr" rid="bib61">Monteiro et al., 2015</xref>). Membrane foci were segmented using Maximum Entropy Threshold (Fiji). Phases of the cell cycle were determined using a classification network trained using fastai deep learning library (2.5.3; <xref ref-type="bibr" rid="bib32">Howard and Gugger, 2020</xref>). Briefly, a Resnet50 pre-trained network (fastai) was trained using manually annotated sets of cells (phase 1–150, phase 2–150, phase 3–150, and missegmented cells - 80) achieving error rate &lt;4%. Trained classifier was used to predict the cell cycle phase of remaining cells.</p></sec><sec id="s4-8"><title>Transmission electron microscopy</title><p><italic>S. aureus</italic> was grown and challenged as described above. Cultures were centrifuged at 1500 × <italic>g</italic>, and the supernatant was removed. Bacterial cells pellets were resuspended in 4% paraformaldehyde/2.5% glutaraldehyde in 0.15 M sodium phosphate buffer, pH 7.4, for 1 hr at room temperature and stored at 4°C. Following three washes with 0.15 M sodium phosphate buffer, pH 7.4, the fixed cell pellets were post-fixed in 1% osmium tetroxide in 0.15 M sodium phosphate buffer, pH 7.4 for 45 min and washed three times with deionized water. The samples were gradually dehydrated with ethanol (30, 50, 75, 100, and 100%) and propylene oxide. The cell pellets were infiltrated with a 1:1 mixture of propylene oxide for and Polybed 812 epoxy resin overnight, followed by a 1:2 mixture of propylene oxide for and Polybed 812 epoxy resin for 3 hr and transferred to 100% resin to embed overnight (Polysciences, Inc,Warrington, PA, USA). Ultrathin sections (70–80 nm) were cut with a diamond knife and mounted on 200 mesh copper grids followed by staining with 4% aqueous uranyl acetate for 12 min and Reynold’s lead citrate for 8 min (<xref ref-type="bibr" rid="bib74">Reynolds, 1963</xref>). Samples were observed using a JEOL JEM-1230 TEM operating at 80 kV (JEOL USA, Inc, Peabody, MA, USA), and images were acquired with a Gatan Orius SC1000 CCD Digital Camera and Gatan Microscopy Suite 3.0 software (Gatan, Inc, Pleasanton, CA, USA).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>is co-inventor on a provisional patent (WO2019018594A1) describing the use of membrane acting agents for potentiating antibiotic efficacy</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Software, Formal analysis, Funding acquisition, Validation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Funding acquisition, Project administration</p></fn><fn fn-type="con" id="con10"><p>Supervision, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-80246-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The raw numerical data for figures 1, 2, 3, 5, and 8 are provided in Source Data files for each figure. The full analysis code for Figure 4 is available on <ext-link ext-link-type="uri" xlink:href="https://github.com/fjorka/bacteria_pa_van_analysis">Github</ext-link> (copy archived at <xref ref-type="bibr" rid="bib86">Sidders et al., 2023</xref>) while all raw imaging data and key processed steps were deposited in Zenodo repository.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Sidders</surname><given-names>AE</given-names></name><name><surname>Kedziora</surname><given-names>KM</given-names></name><name><surname>Arts</surname><given-names>M</given-names></name><name><surname>Daniel</surname><given-names>JM</given-names></name><name><surname>de Benedetti</surname><given-names>S</given-names></name><name><surname>Beam</surname><given-names>JE</given-names></name><name><surname>Bui</surname><given-names>DT</given-names></name><name><surname>Parsons</surname><given-names>JB</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Rowe</surname><given-names>SE</given-names></name><name><surname>Conlon</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Antibiotic-induced accumulation of lipid II synergizes with antimicrobial fatty acids to eradicate bacterial populations - confocal dataset</data-title><source>Zenodo</source><pub-id pub-id-type="doi">10.5281/zenodo.7753640</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported in part by NIH grants R01AI137273, Burroughs Wellcome Fund, and Cystic Fibrosis Foundation Research Grant to BPC. Additionally, this work was supported by the Deutsche Forschungsgemeinschaft project-ID 398967434 – TRR261 to TS. We thank Marianna Pinho for providing COL-<italic>ezra-gfp,</italic> Kim Lewis for providing VISA and VRSA isolates, and Jeremiah Faith for providing the clinical <italic>E faecium</italic> isolate. We thank Pablo Ariel at the Microscopy Service Laboratory (MSL) at UNC for helping optimize fluorescence microscopy experiments. We thank Kristen White at the MSL for performing TEM imaging and processing. The MSL, Department of Pathology and Laboratory Medicine, is supported in part by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center. The image analysis was performed at the Bioinformatics and Analytics Research Collaborative (BARC) which is supported in part by the UNC School of Medicine Strategic Plan and Office of Research. KMK is supported by grant number 2020–225716 from the Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation. We thank Virginie Papadopoulou, Phil Durham, Lauren Radlinski, Baggio Evangelista, and Joey Ragusa for thoughtful discussions.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwala</surname><given-names>V</given-names></name><name><surname>Mogno</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Britton</surname><given-names>GJ</given-names></name><name><surname>Chen-Liaw</surname><given-names>A</given-names></name><name><surname>Mitcham</surname><given-names>J</given-names></name><name><surname>Bongers</surname><given-names>G</given-names></name><name><surname>Gevers</surname><given-names>D</given-names></name><name><surname>Clemente</surname><given-names>JC</given-names></name><name><surname>Colombel</surname><given-names>JF</given-names></name><name><surname>Grinspan</surname><given-names>A</given-names></name><name><surname>Faith</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes</article-title><source>Nature Microbiology</source><volume>6</volume><fpage>1309</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1038/s41564-021-00966-0</pub-id><pub-id pub-id-type="pmid">34580445</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aminov</surname><given-names>RI</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A brief history of the antibiotic era: lessons learned and challenges for the future</article-title><source>Frontiers in Microbiology</source><volume>1</volume><elocation-id>134</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2010.00134</pub-id><pub-id pub-id-type="pmid">21687759</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anjuwon-Foster</surname><given-names>BR</given-names></name><name><surname>Tamayo</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A genetic switch controls the production of flagella and toxins in Clostridium difficile</article-title><source>PLOS Genetics</source><volume>13</volume><elocation-id>e1006701</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006701</pub-id><pub-id pub-id-type="pmid">28346491</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Argáez</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><source>Topical Antibiotics for Infection Prevention: A Review of the Clinical Effectiveness and Guidelines</source><publisher-name>Canadian Agency for Drugs and Technologies in Health</publisher-name></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beavers</surname><given-names>WN</given-names></name><name><surname>Munneke</surname><given-names>MJ</given-names></name><name><surname>Stackhouse</surname><given-names>AR</given-names></name><name><surname>Freiberg</surname><given-names>JA</given-names></name><name><surname>Skaar</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Host polyunsaturated fatty acids potentiate aminoglycoside killing of <italic>Staphylococcus aureus</italic></article-title><source>Microbiology Spectrum</source><volume>10</volume><elocation-id>e0276721</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.02767-21</pub-id><pub-id pub-id-type="pmid">35377191</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belley</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name><name><surname>Beveridge</surname><given-names>T</given-names></name><name><surname>Parr</surname><given-names>T</given-names></name><name><surname>Moeck</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ultrastructural effects of oritavancin on methicillin-resistant <italic>Staphylococcus aureus</italic> and vancomycin-resistant enterococcus</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>53</volume><fpage>800</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1128/AAC.00603-08</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Hansford</surname><given-names>KA</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Mark</surname><given-names>AE</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Developments in glycopeptide antibiotics</article-title><source>ACS Infectious Diseases</source><volume>4</volume><fpage>715</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00258</pub-id><pub-id pub-id-type="pmid">29363950</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blattner</surname><given-names>FR</given-names></name><name><surname>Plunkett</surname><given-names>G</given-names></name><name><surname>Bloch</surname><given-names>CA</given-names></name><name><surname>Perna</surname><given-names>NT</given-names></name><name><surname>Burland</surname><given-names>V</given-names></name><name><surname>Riley</surname><given-names>M</given-names></name><name><surname>Collado-Vides</surname><given-names>J</given-names></name><name><surname>Glasner</surname><given-names>JD</given-names></name><name><surname>Rode</surname><given-names>CK</given-names></name><name><surname>Mayhew</surname><given-names>GF</given-names></name><name><surname>Gregor</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>NW</given-names></name><name><surname>Kirkpatrick</surname><given-names>HA</given-names></name><name><surname>Goeden</surname><given-names>MA</given-names></name><name><surname>Rose</surname><given-names>DJ</given-names></name><name><surname>Mau</surname><given-names>B</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The complete genome sequence of <italic>Escherichia coli</italic> K-12</article-title><source>Science</source><volume>277</volume><fpage>1453</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1126/science.277.5331.1453</pub-id><pub-id pub-id-type="pmid">9278503</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudjemaa</surname><given-names>R</given-names></name><name><surname>Cabriel</surname><given-names>C</given-names></name><name><surname>Dubois-Brissonnet</surname><given-names>F</given-names></name><name><surname>Bourg</surname><given-names>N</given-names></name><name><surname>Dupuis</surname><given-names>G</given-names></name><name><surname>Gruss</surname><given-names>A</given-names></name><name><surname>Lévêque-Fort</surname><given-names>S</given-names></name><name><surname>Briandet</surname><given-names>R</given-names></name><name><surname>Fontaine-Aupart</surname><given-names>MP</given-names></name><name><surname>Steenkeste</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Impact of bacterial membrane fatty acid composition on the failure of daptomycin to kill <italic>Staphylococcus aureus</italic></article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>62</volume><fpage>e00023</fpage><lpage>e00018</lpage><pub-id pub-id-type="doi">10.1128/AAC.00023-18</pub-id><pub-id pub-id-type="pmid">29735564</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burtenshaw</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1942">1942</year><article-title>The mechanism of self-disinfection of the human skin and its appendages</article-title><source>The Journal of Hygiene</source><volume>42</volume><fpage>184</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1017/s0022172400035373</pub-id><pub-id pub-id-type="pmid">20475622</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartron</surname><given-names>ML</given-names></name><name><surname>England</surname><given-names>SR</given-names></name><name><surname>Chiriac</surname><given-names>AI</given-names></name><name><surname>Josten</surname><given-names>M</given-names></name><name><surname>Turner</surname><given-names>R</given-names></name><name><surname>Rauter</surname><given-names>Y</given-names></name><name><surname>Hurd</surname><given-names>A</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Foster</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Bactericidal activity of the human skin fatty acid cis-6-hexadecanoic acid on <italic>Staphylococcus aureus</italic></article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>58</volume><fpage>3599</fpage><lpage>3609</lpage><pub-id pub-id-type="doi">10.1128/AAC.01043-13</pub-id><pub-id pub-id-type="pmid">24709265</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chugunov</surname><given-names>A</given-names></name><name><surname>Pyrkova</surname><given-names>D</given-names></name><name><surname>Nolde</surname><given-names>D</given-names></name><name><surname>Polyansky</surname><given-names>A</given-names></name><name><surname>Pentkovsky</surname><given-names>V</given-names></name><name><surname>Efremov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lipid-II forms potential “ landing terrain” for lantibiotics in simulated bacterial membrane</article-title><source>Scientific Reports</source><volume>3</volume><elocation-id>1678</elocation-id><pub-id pub-id-type="doi">10.1038/srep01678</pub-id><pub-id pub-id-type="pmid">23588060</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churchward</surname><given-names>CP</given-names></name><name><surname>Alany</surname><given-names>RG</given-names></name><name><surname>Snyder</surname><given-names>LAS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Alternative antimicrobials: the properties of fatty acids and monoglycerides</article-title><source>Critical Reviews in Microbiology</source><volume>44</volume><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1080/1040841X.2018.1467875</pub-id><pub-id pub-id-type="pmid">29733249</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conlon</surname><given-names>BP</given-names></name><name><surname>Geoghegan</surname><given-names>JA</given-names></name><name><surname>Waters</surname><given-names>EM</given-names></name><name><surname>McCarthy</surname><given-names>H</given-names></name><name><surname>Rowe</surname><given-names>SE</given-names></name><name><surname>Davies</surname><given-names>JR</given-names></name><name><surname>Schaeffer</surname><given-names>CR</given-names></name><name><surname>Foster</surname><given-names>TJ</given-names></name><name><surname>Fey</surname><given-names>PD</given-names></name><name><surname>O’Gara</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Role for the a domain of unprocessed accumulation-associated protein (Aap) in the attachment phase of the Staphylococcus epidermidis biofilm phenotype</article-title><source>Journal of Bacteriology</source><volume>196</volume><fpage>4268</fpage><lpage>4275</lpage><pub-id pub-id-type="doi">10.1128/JB.01946-14</pub-id><pub-id pub-id-type="pmid">25266380</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conlon</surname><given-names>BP</given-names></name><name><surname>Rowe</surname><given-names>SE</given-names></name><name><surname>Gandt</surname><given-names>AB</given-names></name><name><surname>Nuxoll</surname><given-names>AS</given-names></name><name><surname>Donegan</surname><given-names>NP</given-names></name><name><surname>Zalis</surname><given-names>EA</given-names></name><name><surname>Clair</surname><given-names>G</given-names></name><name><surname>Adkins</surname><given-names>JN</given-names></name><name><surname>Cheung</surname><given-names>AL</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Persister formation in <italic>Staphylococcus aureus</italic> is associated with ATP depletion</article-title><source>Nature Microbiology</source><volume>1</volume><elocation-id>16051</elocation-id><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.51</pub-id><pub-id pub-id-type="pmid">27572649</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Oliveira</surname><given-names>DMP</given-names></name><name><surname>Forde</surname><given-names>BM</given-names></name><name><surname>Kidd</surname><given-names>TJ</given-names></name><name><surname>Harris</surname><given-names>PNA</given-names></name><name><surname>Schembri</surname><given-names>MA</given-names></name><name><surname>Beatson</surname><given-names>SA</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name><name><surname>Walker</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antimicrobial resistance in ESKAPE pathogens</article-title><source>Clinical Microbiology Reviews</source><volume>33</volume><fpage>e00181</fpage><lpage>e00119</lpage><pub-id pub-id-type="doi">10.1128/CMR.00181-19</pub-id><pub-id pub-id-type="pmid">32404435</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Do</surname><given-names>TQ</given-names></name><name><surname>Moshkani</surname><given-names>S</given-names></name><name><surname>Castillo</surname><given-names>P</given-names></name><name><surname>Anunta</surname><given-names>S</given-names></name><name><surname>Pogosyan</surname><given-names>A</given-names></name><name><surname>Cheung</surname><given-names>A</given-names></name><name><surname>Marbois</surname><given-names>B</given-names></name><name><surname>Faull</surname><given-names>KF</given-names></name><name><surname>Ernst</surname><given-names>W</given-names></name><name><surname>Chiang</surname><given-names>SM</given-names></name><name><surname>Fujii</surname><given-names>G</given-names></name><name><surname>Clarke</surname><given-names>CF</given-names></name><name><surname>Foster</surname><given-names>K</given-names></name><name><surname>Porter</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid</article-title><source>Journal of Immunology</source><volume>181</volume><fpage>4177</fpage><lpage>4187</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.6.4177</pub-id><pub-id pub-id-type="pmid">18768875</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epand</surname><given-names>RM</given-names></name><name><surname>Walker</surname><given-names>C</given-names></name><name><surname>Epand</surname><given-names>RF</given-names></name><name><surname>Magarvey</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Molecular mechanisms of membrane targeting antibiotics</article-title><source>Biochimica et Biophysica Acta</source><volume>1858</volume><fpage>980</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2015.10.018</pub-id><pub-id pub-id-type="pmid">26514603</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falagas</surname><given-names>ME</given-names></name><name><surname>Vouloumanou</surname><given-names>EK</given-names></name><name><surname>Samonis</surname><given-names>G</given-names></name><name><surname>Vardakas</surname><given-names>KZ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fosfomycin</article-title><source>Clinical Microbiology Reviews</source><volume>29</volume><fpage>321</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1128/CMR.00068-15</pub-id><pub-id pub-id-type="pmid">26960938</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fey</surname><given-names>PD</given-names></name><name><surname>Endres</surname><given-names>JL</given-names></name><name><surname>Yajjala</surname><given-names>VK</given-names></name><name><surname>Widhelm</surname><given-names>TJ</given-names></name><name><surname>Boissy</surname><given-names>RJ</given-names></name><name><surname>Bose</surname><given-names>JL</given-names></name><name><surname>Bayles</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A genetic resource for rapid and comprehensive phenotype screening of nonessential <italic>Staphylococcus aureus</italic> genes</article-title><source>MBio</source><volume>4</volume><elocation-id>e00537-12</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00537-12</pub-id><pub-id pub-id-type="pmid">23404398</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antimicrobial activity of host-derived lipids</article-title><source>Antibiotics</source><volume>9</volume><elocation-id>75</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics9020075</pub-id><pub-id pub-id-type="pmid">32054068</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Fernández</surname><given-names>E</given-names></name><name><surname>Koch</surname><given-names>G</given-names></name><name><surname>Wagner</surname><given-names>RM</given-names></name><name><surname>Fekete</surname><given-names>A</given-names></name><name><surname>Stengel</surname><given-names>ST</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Mielich-Süss</surname><given-names>B</given-names></name><name><surname>Geibel</surname><given-names>S</given-names></name><name><surname>Markert</surname><given-names>SM</given-names></name><name><surname>Stigloher</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Membrane microdomain disassembly inhibits MRSA antibiotic resistance</article-title><source>Cell</source><volume>171</volume><fpage>1354</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.012</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgel</surname><given-names>P</given-names></name><name><surname>Crozat</surname><given-names>K</given-names></name><name><surname>Lauth</surname><given-names>X</given-names></name><name><surname>Makrantonaki</surname><given-names>E</given-names></name><name><surname>Seltmann</surname><given-names>H</given-names></name><name><surname>Sovath</surname><given-names>S</given-names></name><name><surname>Hoebe</surname><given-names>K</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Rutschmann</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Bigby</surname><given-names>T</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name><name><surname>Zouboulis</surname><given-names>CC</given-names></name><name><surname>Beutler</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A Toll-like receptor 2-responsive lipid effector pathway protects mammals against skin infections with gram-positive bacteria</article-title><source>Infection and Immunity</source><volume>73</volume><fpage>4512</fpage><lpage>4521</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.8.4512-4521.2005</pub-id><pub-id pub-id-type="pmid">16040962</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>DA</given-names></name><name><surname>Wenzel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Multitarget approaches against multiresistant superbugs</article-title><source>ACS Infectious Diseases</source><volume>6</volume><fpage>1346</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00001</pub-id><pub-id pub-id-type="pmid">32156116</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>DA</given-names></name><name><surname>Wenzel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>More than a pore: a current perspective on the in vivo mode of action of the lipopeptide antibiotic daptomycin</article-title><source>Antibiotics</source><volume>9</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics9010017</pub-id><pub-id pub-id-type="pmid">31947747</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grein</surname><given-names>F</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Docking on lipid II-A widespread mechanism for potent bactericidal activities of antibiotic peptides</article-title><source>Journal of Molecular Biology</source><volume>431</volume><fpage>3520</fpage><lpage>3530</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.05.014</pub-id><pub-id pub-id-type="pmid">31100388</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grein</surname><given-names>F</given-names></name><name><surname>Müller</surname><given-names>A</given-names></name><name><surname>Scherer</surname><given-names>KM</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ludwig</surname><given-names>KC</given-names></name><name><surname>Klöckner</surname><given-names>A</given-names></name><name><surname>Strach</surname><given-names>M</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name><name><surname>Kubitscheck</surname><given-names>U</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ca2+-daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1455</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15257-1</pub-id><pub-id pub-id-type="pmid">32193379</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardt</surname><given-names>P</given-names></name><name><surname>Engels</surname><given-names>I</given-names></name><name><surname>Rausch</surname><given-names>M</given-names></name><name><surname>Gajdiss</surname><given-names>M</given-names></name><name><surname>Ulm</surname><given-names>H</given-names></name><name><surname>Sass</surname><given-names>P</given-names></name><name><surname>Ohlsen</surname><given-names>K</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name><name><surname>Bierbaum</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Grein</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The cell wall precursor lipid II acts as a molecular signal for the Ser/Thr kinase PknB of <italic>Staphylococcus aureus</italic></article-title><source>International Journal of Medical Microbiology</source><volume>307</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2016.12.001</pub-id><pub-id pub-id-type="pmid">27989665</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbert</surname><given-names>S</given-names></name><name><surname>Ziebandt</surname><given-names>AK</given-names></name><name><surname>Ohlsen</surname><given-names>K</given-names></name><name><surname>Schäfer</surname><given-names>T</given-names></name><name><surname>Hecker</surname><given-names>M</given-names></name><name><surname>Albrecht</surname><given-names>D</given-names></name><name><surname>Novick</surname><given-names>R</given-names></name><name><surname>Götz</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Repair of global regulators in <italic>Staphylococcus aureus</italic> 8325 and comparative analysis with other clinical isolates</article-title><source>Infection and Immunity</source><volume>78</volume><fpage>2877</fpage><lpage>2889</lpage><pub-id pub-id-type="doi">10.1128/IAI.00088-10</pub-id><pub-id pub-id-type="pmid">20212089</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>DJ</given-names></name><name><surname>Henry-Stanley</surname><given-names>MJ</given-names></name><name><surname>Wells</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Antibacterial synergy of glycerol monolaurate and aminoglycosides in <italic>Staphylococcus aureus</italic> biofilms</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>58</volume><fpage>6970</fpage><lpage>6973</lpage><pub-id pub-id-type="doi">10.1128/AAC.03672-14</pub-id><pub-id pub-id-type="pmid">25182634</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>PWS</given-names></name><name><surname>Moldoveanu</surname><given-names>AL</given-names></name><name><surname>Sargen</surname><given-names>M</given-names></name><name><surname>Ronneau</surname><given-names>S</given-names></name><name><surname>Glegola-Madejska</surname><given-names>I</given-names></name><name><surname>Beetham</surname><given-names>C</given-names></name><name><surname>Fisher</surname><given-names>RA</given-names></name><name><surname>Helaine</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The vulnerable versatility of salmonella antibiotic persisters during infection</article-title><source>Cell Host &amp; Microbe</source><volume>29</volume><fpage>1757</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2021.10.002</pub-id><pub-id pub-id-type="pmid">34731646</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>J</given-names></name><name><surname>Gugger</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fastai: a layered API for deep learning</article-title><source>Information</source><volume>11</volume><elocation-id>108</elocation-id><pub-id pub-id-type="doi">10.3390/info11020108</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurdle</surname><given-names>JG</given-names></name><name><surname>O’Neill</surname><given-names>AJ</given-names></name><name><surname>Chopra</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections</article-title><source>Nature Reviews. Microbiology</source><volume>9</volume><fpage>62</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2474</pub-id><pub-id pub-id-type="pmid">21164535</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabara</surname><given-names>JJ</given-names></name><name><surname>Swieczkowski</surname><given-names>DM</given-names></name><name><surname>Conley</surname><given-names>AJ</given-names></name><name><surname>Truant</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="1972">1972</year><article-title>Fatty acids and derivatives as antimicrobial agents</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>2</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1128/AAC.2.1.23</pub-id><pub-id pub-id-type="pmid">4670656</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>AD</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Braughton</surname><given-names>KR</given-names></name><name><surname>Whitney</surname><given-names>AR</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Mathema</surname><given-names>B</given-names></name><name><surname>Mediavilla</surname><given-names>JR</given-names></name><name><surname>Byrne</surname><given-names>KA</given-names></name><name><surname>Parkins</surname><given-names>LD</given-names></name><name><surname>Tenover</surname><given-names>FC</given-names></name><name><surname>Kreiswirth</surname><given-names>BN</given-names></name><name><surname>Musser</surname><given-names>JM</given-names></name><name><surname>DeLeo</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Epidemic community-associated methicillin-resistant <italic>Staphylococcus aureus</italic>: recent clonal expansion and diversification</article-title><source>PNAS</source><volume>105</volume><fpage>1327</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.1073/pnas.0710217105</pub-id><pub-id pub-id-type="pmid">18216255</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Hendricks</surname><given-names>GL</given-names></name><name><surname>Van Tyne</surname><given-names>D</given-names></name><name><surname>Steele</surname><given-names>AD</given-names></name><name><surname>Keohane</surname><given-names>CE</given-names></name><name><surname>Fricke</surname><given-names>N</given-names></name><name><surname>Conery</surname><given-names>AL</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Rajamuthiah</surname><given-names>R</given-names></name><name><surname>Fuchs</surname><given-names>BB</given-names></name><name><surname>Vlahovska</surname><given-names>PM</given-names></name><name><surname>Wuest</surname><given-names>WM</given-names></name><name><surname>Gilmore</surname><given-names>MS</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Ausubel</surname><given-names>FM</given-names></name><name><surname>Mylonakis</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A new class of synthetic retinoid antibiotics effective against bacterial persisters</article-title><source>Nature</source><volume>556</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nature26157</pub-id><pub-id pub-id-type="pmid">29590091</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Zou</surname><given-names>G</given-names></name><name><surname>Hari</surname><given-names>TPA</given-names></name><name><surname>Wilt</surname><given-names>IK</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Galle</surname><given-names>N</given-names></name><name><surname>Faizi</surname><given-names>HA</given-names></name><name><surname>Hendricks</surname><given-names>GL</given-names></name><name><surname>Tori</surname><given-names>K</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Steele</surname><given-names>AD</given-names></name><name><surname>Csatary</surname><given-names>EE</given-names></name><name><surname>Dekarske</surname><given-names>MM</given-names></name><name><surname>Rosen</surname><given-names>JL</given-names></name><name><surname>Ribeiro</surname><given-names>NdQ</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Port</surname><given-names>J</given-names></name><name><surname>Fuchs</surname><given-names>BB</given-names></name><name><surname>Vlahovska</surname><given-names>PM</given-names></name><name><surname>Wuest</surname><given-names>WM</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Ausubel</surname><given-names>FM</given-names></name><name><surname>Mylonakis</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A selective membrane-targeting repurposed antibiotic with activity against persistent methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>PNAS</source><volume>116</volume><fpage>16529</fpage><lpage>16534</lpage><pub-id pub-id-type="doi">10.1073/pnas.1904700116</pub-id><pub-id pub-id-type="pmid">31358625</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodicek</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1945">1945</year><article-title>The effect of unsaturated fatty acids on Lactobacillus helveticus and other gram-positive micro-organisms</article-title><source>The Biochemical Journal</source><volume>39</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1042/bj0390078</pub-id><pub-id pub-id-type="pmid">16747862</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollef</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Limitations of vancomycin in the management of resistant staphylococcal infections</article-title><source>Clinical Infectious Diseases</source><volume>45 Suppl 3</volume><fpage>S191</fpage><lpage>S195</lpage><pub-id pub-id-type="doi">10.1086/519470</pub-id><pub-id pub-id-type="pmid">17712746</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>König</surname><given-names>C</given-names></name><name><surname>Simmen</surname><given-names>HP</given-names></name><name><surname>Blaser</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Bacterial concentrations in pus and infected peritoneal fluid -- implications for bactericidal activity of antibiotics</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>42</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1093/jac/42.2.227</pub-id><pub-id pub-id-type="pmid">9738841</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosowska-Shick</surname><given-names>K</given-names></name><name><surname>Ednie</surname><given-names>LM</given-names></name><name><surname>McGhee</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Todd</surname><given-names>CD</given-names></name><name><surname>Wehler</surname><given-names>A</given-names></name><name><surname>Appelbaum</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant <italic>Staphylococcus aureus</italic> at hershey medical center</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>52</volume><fpage>4510</fpage><lpage>4513</lpage><pub-id pub-id-type="doi">10.1128/AAC.01073-08</pub-id><pub-id pub-id-type="pmid">18838583</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucherak</surname><given-names>OA</given-names></name><name><surname>Oncul</surname><given-names>S</given-names></name><name><surname>Darwich</surname><given-names>Z</given-names></name><name><surname>Yushchenko</surname><given-names>DA</given-names></name><name><surname>Arntz</surname><given-names>Y</given-names></name><name><surname>Didier</surname><given-names>P</given-names></name><name><surname>Mély</surname><given-names>Y</given-names></name><name><surname>Klymchenko</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Switchable Nile red-based probe for cholesterol and lipid order at the outer leaflet of biomembranes</article-title><source>Journal of the American Chemical Society</source><volume>132</volume><fpage>4907</fpage><lpage>4916</lpage><pub-id pub-id-type="doi">10.1021/ja100351w</pub-id><pub-id pub-id-type="pmid">20225874</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuiack</surname><given-names>RC</given-names></name><name><surname>Veldhuizen</surname><given-names>RAW</given-names></name><name><surname>McGavin</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Novel functions and signaling specificity for the GRAS sensor kinase of <italic>Staphylococcus aureus</italic> in response to acidic pH</article-title><source>Journal of Bacteriology</source><volume>202</volume><elocation-id>e00219-20</elocation-id><pub-id pub-id-type="doi">10.1128/JB.00219-20</pub-id><pub-id pub-id-type="pmid">32868405</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuru</surname><given-names>E</given-names></name><name><surname>Tekkam</surname><given-names>S</given-names></name><name><surname>Hall</surname><given-names>E</given-names></name><name><surname>Brun</surname><given-names>YV</given-names></name><name><surname>Van Nieuwenhze</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Synthesis of fluorescent D-amino acids and their use for probing peptidoglycan synthesis and bacterial growth in situ</article-title><source>Nature Protocols</source><volume>10</volume><fpage>33</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/nprot.2014.197</pub-id><pub-id pub-id-type="pmid">25474031</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamar</surname><given-names>RV</given-names></name></person-group><year iso-8601-date="1911">1911</year><article-title>CHEMO-IMMUNOLOGICAL studies on localized infections: second paper: lysis of the pneumococcus and hemolysis by certain fatty acids and their alkali soaps</article-title><source>The Journal of Experimental Medicine</source><volume>13</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1084/jem.13.3.380</pub-id><pub-id pub-id-type="pmid">19867419</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaPlante</surname><given-names>KL</given-names></name><name><surname>Rybak</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Impact of high-inoculum <italic>Staphylococcus aureus</italic> on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>48</volume><fpage>4665</fpage><lpage>4672</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.12.4665-4672.2004</pub-id><pub-id pub-id-type="pmid">15561842</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Labroli</surname><given-names>M</given-names></name><name><surname>Koseoglu</surname><given-names>S</given-names></name><name><surname>Zuck</surname><given-names>P</given-names></name><name><surname>Mayhood</surname><given-names>T</given-names></name><name><surname>Gill</surname><given-names>C</given-names></name><name><surname>Mann</surname><given-names>P</given-names></name><name><surname>Sher</surname><given-names>X</given-names></name><name><surname>Ha</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>SW</given-names></name><name><surname>Mandal</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Tawa</surname><given-names>P</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Kuvelkar</surname><given-names>R</given-names></name><name><surname>DeVito</surname><given-names>K</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Batchlett</surname><given-names>M</given-names></name><name><surname>Balibar</surname><given-names>CJ</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Murgolo</surname><given-names>N</given-names></name><name><surname>Garlisi</surname><given-names>CG</given-names></name><name><surname>Sheth</surname><given-names>PR</given-names></name><name><surname>Flattery</surname><given-names>A</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Roemer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TarO-specific inhibitors of wall teichoic acid biosynthesis restore β-lactam efficacy against methicillin-resistant staphylococci</article-title><source>Science Translational Medicine</source><volume>8</volume><elocation-id>329ra32</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aad7364</pub-id><pub-id pub-id-type="pmid">26962156</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin-Reisman</surname><given-names>I</given-names></name><name><surname>Ronin</surname><given-names>I</given-names></name><name><surname>Gefen</surname><given-names>O</given-names></name><name><surname>Braniss</surname><given-names>I</given-names></name><name><surname>Shoresh</surname><given-names>N</given-names></name><name><surname>Balaban</surname><given-names>NQ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Antibiotic tolerance facilitates the evolution of resistance</article-title><source>Science</source><volume>355</volume><fpage>826</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1126/science.aaj2191</pub-id><pub-id pub-id-type="pmid">28183996</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The science of antibiotic discovery</article-title><source>Cell</source><volume>181</volume><fpage>29</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.056</pub-id><pub-id pub-id-type="pmid">32197064</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>LL</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Peoples</surname><given-names>AJ</given-names></name><name><surname>Spoering</surname><given-names>AL</given-names></name><name><surname>Engels</surname><given-names>I</given-names></name><name><surname>Conlon</surname><given-names>BP</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Schäberle</surname><given-names>TF</given-names></name><name><surname>Hughes</surname><given-names>DE</given-names></name><name><surname>Epstein</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Lazarides</surname><given-names>L</given-names></name><name><surname>Steadman</surname><given-names>VA</given-names></name><name><surname>Cohen</surname><given-names>DR</given-names></name><name><surname>Felix</surname><given-names>CR</given-names></name><name><surname>Fetterman</surname><given-names>KA</given-names></name><name><surname>Millett</surname><given-names>WP</given-names></name><name><surname>Nitti</surname><given-names>AG</given-names></name><name><surname>Zullo</surname><given-names>AM</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A new antibiotic kills pathogens without detectable resistance</article-title><source>Nature</source><volume>517</volume><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1038/nature14098</pub-id><pub-id pub-id-type="pmid">25561178</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Gefen</surname><given-names>O</given-names></name><name><surname>Ronin</surname><given-names>I</given-names></name><name><surname>Bar-Meir</surname><given-names>M</given-names></name><name><surname>Balaban</surname><given-names>NQ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Effect of tolerance on the evolution of antibiotic resistance under drug combinations</article-title><source>Science</source><volume>367</volume><fpage>200</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1126/science.aay3041</pub-id><pub-id pub-id-type="pmid">31919223</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loffredo</surname><given-names>MR</given-names></name><name><surname>Savini</surname><given-names>F</given-names></name><name><surname>Bobone</surname><given-names>S</given-names></name><name><surname>Casciaro</surname><given-names>B</given-names></name><name><surname>Franzyk</surname><given-names>H</given-names></name><name><surname>Mangoni</surname><given-names>ML</given-names></name><name><surname>Stella</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inoculum effect of antimicrobial peptides</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2014364118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2014364118</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>VA</given-names></name><name><surname>Wacnik</surname><given-names>K</given-names></name><name><surname>Turner</surname><given-names>RD</given-names></name><name><surname>Cotterell</surname><given-names>BE</given-names></name><name><surname>Walther</surname><given-names>CG</given-names></name><name><surname>Fenn</surname><given-names>SJ</given-names></name><name><surname>Grein</surname><given-names>F</given-names></name><name><surname>Wollman</surname><given-names>AJM</given-names></name><name><surname>Leake</surname><given-names>MC</given-names></name><name><surname>Olivier</surname><given-names>N</given-names></name><name><surname>Cadby</surname><given-names>A</given-names></name><name><surname>Mesnage</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Foster</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Molecular coordination of <italic>Staphylococcus aureus</italic> cell division</article-title><source>eLife</source><volume>7</volume><elocation-id>e32057</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.32057</pub-id><pub-id pub-id-type="pmid">29465397</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maharshak</surname><given-names>N</given-names></name><name><surname>Huh</surname><given-names>EY</given-names></name><name><surname>Paiboonrungruang</surname><given-names>C</given-names></name><name><surname>Shanahan</surname><given-names>M</given-names></name><name><surname>Thurlow</surname><given-names>L</given-names></name><name><surname>Herzog</surname><given-names>J</given-names></name><name><surname>Djukic</surname><given-names>Z</given-names></name><name><surname>Orlando</surname><given-names>R</given-names></name><name><surname>Pawlinski</surname><given-names>R</given-names></name><name><surname>Ellermann</surname><given-names>M</given-names></name><name><surname>Borst</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Dotan</surname><given-names>I</given-names></name><name><surname>Sartor</surname><given-names>RB</given-names></name><name><surname>Carroll</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title><italic>Enterococcus faecalis</italic> gelatinase mediates intestinal permeability via protease-activated receptor 2</article-title><source>Infection and Immunity</source><volume>83</volume><fpage>2762</fpage><lpage>2770</lpage><pub-id pub-id-type="doi">10.1128/IAI.00425-15</pub-id><pub-id pub-id-type="pmid">25916983</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manson</surname><given-names>JM</given-names></name><name><surname>Keis</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>JMB</given-names></name><name><surname>Cook</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Acquired bacitracin resistance in <italic>Enterococcus faecalis</italic> is mediated by an ABC transporter and a novel regulatory protein, BcrR</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>48</volume><fpage>3743</fpage><lpage>3748</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.10.3743-3748.2004</pub-id><pub-id pub-id-type="pmid">15388429</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JK</given-names></name><name><surname>Sheehan</surname><given-names>JP</given-names></name><name><surname>Bratton</surname><given-names>BP</given-names></name><name><surname>Moore</surname><given-names>GM</given-names></name><name><surname>Mateus</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>SHJ</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Typas</surname><given-names>A</given-names></name><name><surname>Savitski</surname><given-names>MM</given-names></name><name><surname>Wilson</surname><given-names>MZ</given-names></name><name><surname>Gitai</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A dual-mechanism antibiotic kills gram-negative bacteria and avoids drug resistance</article-title><source>Cell</source><volume>181</volume><fpage>1518</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.005</pub-id><pub-id pub-id-type="pmid">32497502</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuinness</surname><given-names>WA</given-names></name><name><surname>Malachowa</surname><given-names>N</given-names></name><name><surname>DeLeo</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Vancomycin resistance in <italic>Staphylococcus aureus</italic></article-title><source>Yale J Biol Med</source><volume>90</volume><fpage>269</fpage><lpage>281</lpage></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>RD</given-names></name><name><surname>Brown</surname><given-names>KE</given-names></name><name><surname>Morse</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Inhibitory action of fatty acids on the growth of neisseria gonorrhoeae</article-title><source>Infection and Immunity</source><volume>17</volume><fpage>303</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1128/iai.17.2.303-312.1977</pub-id><pub-id pub-id-type="pmid">19358</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mingeot-Leclercq</surname><given-names>MP</given-names></name><name><surname>Décout</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bacterial lipid membranes as promising targets to fight antimicrobial resistance, molecular foundations and illustration through the renewal of aminoglycoside antibiotics and emergence of amphiphilic aminoglycosides</article-title><source>MedChemComm</source><volume>7</volume><fpage>586</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1039/C5MD00503E</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>MF</given-names></name><name><surname>Abdelkhalek</surname><given-names>A</given-names></name><name><surname>Seleem</surname><given-names>MN</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular <italic>Staphylococcus aureus</italic></article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>29707</elocation-id><pub-id pub-id-type="doi">10.1038/srep29707</pub-id><pub-id pub-id-type="pmid">27405275</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname><given-names>JM</given-names></name><name><surname>Fernandes</surname><given-names>PB</given-names></name><name><surname>Vaz</surname><given-names>F</given-names></name><name><surname>Pereira</surname><given-names>AR</given-names></name><name><surname>Tavares</surname><given-names>AC</given-names></name><name><surname>Ferreira</surname><given-names>MT</given-names></name><name><surname>Pereira</surname><given-names>PM</given-names></name><name><surname>Veiga</surname><given-names>H</given-names></name><name><surname>Kuru</surname><given-names>E</given-names></name><name><surname>VanNieuwenhze</surname><given-names>MS</given-names></name><name><surname>Brun</surname><given-names>YV</given-names></name><name><surname>Filipe</surname><given-names>SR</given-names></name><name><surname>Pinho</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell shape dynamics during the staphylococcal cell cycle</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>8055</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms9055</pub-id><pub-id pub-id-type="pmid">26278781</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname><given-names>JM</given-names></name><name><surname>Pereira</surname><given-names>AR</given-names></name><name><surname>Reichmann</surname><given-names>NT</given-names></name><name><surname>Saraiva</surname><given-names>BM</given-names></name><name><surname>Fernandes</surname><given-names>PB</given-names></name><name><surname>Veiga</surname><given-names>H</given-names></name><name><surname>Tavares</surname><given-names>AC</given-names></name><name><surname>Santos</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>MT</given-names></name><name><surname>Macário</surname><given-names>V</given-names></name><name><surname>VanNieuwenhze</surname><given-names>MS</given-names></name><name><surname>Filipe</surname><given-names>SR</given-names></name><name><surname>Pinho</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Peptidoglycan synthesis drives an ftsz-treadmilling-independent step of cytokinesis</article-title><source>Nature</source><volume>554</volume><fpage>528</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/nature25506</pub-id><pub-id pub-id-type="pmid">29443967</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>A</given-names></name><name><surname>Münch</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>Y</given-names></name><name><surname>Reder-Christ</surname><given-names>K</given-names></name><name><surname>Schiffer</surname><given-names>G</given-names></name><name><surname>Bendas</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>H</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Brötz-Oesterhelt</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Lipodepsipeptide empedopeptin inhibits cell wall biosynthesis through Ca2+-dependent complex formation with peptidoglycan precursors</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>20270</fpage><lpage>20280</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.369561</pub-id><pub-id pub-id-type="pmid">22514280</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>A</given-names></name><name><surname>Wenzel</surname><given-names>M</given-names></name><name><surname>Strahl</surname><given-names>H</given-names></name><name><surname>Grein</surname><given-names>F</given-names></name><name><surname>Saaki</surname><given-names>TNV</given-names></name><name><surname>Kohl</surname><given-names>B</given-names></name><name><surname>Siersma</surname><given-names>T</given-names></name><name><surname>Bandow</surname><given-names>JE</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Hamoen</surname><given-names>LW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains</article-title><source>PNAS</source><volume>113</volume><fpage>E7077</fpage><lpage>E7086</lpage><pub-id pub-id-type="doi">10.1073/pnas.1611173113</pub-id><pub-id pub-id-type="pmid">27791134</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>A</given-names></name><name><surname>Klöckner</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting a cell wall biosynthesis hot spot</article-title><source>Natural Product Reports</source><volume>34</volume><fpage>909</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1039/c7np00012j</pub-id><pub-id pub-id-type="pmid">28675405</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>Y</given-names></name><name><surname>Ohlsen</surname><given-names>K</given-names></name><name><surname>Donat</surname><given-names>S</given-names></name><name><surname>Engelmann</surname><given-names>S</given-names></name><name><surname>Kusch</surname><given-names>H</given-names></name><name><surname>Albrecht</surname><given-names>D</given-names></name><name><surname>Cartron</surname><given-names>M</given-names></name><name><surname>Hurd</surname><given-names>A</given-names></name><name><surname>Foster</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The effect of skin fatty acids on <italic>Staphylococcus aureus</italic></article-title><source>Archives of Microbiology</source><volume>197</volume><fpage>245</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1007/s00203-014-1048-1</pub-id><pub-id pub-id-type="pmid">25325933</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>JB</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Frank</surname><given-names>MW</given-names></name><name><surname>Jackson</surname><given-names>P</given-names></name><name><surname>Rock</surname><given-names>CO</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from <italic>Staphylococcus aureus</italic></article-title><source>Journal of Bacteriology</source><volume>194</volume><fpage>5294</fpage><lpage>5304</lpage><pub-id pub-id-type="doi">10.1128/JB.00743-12</pub-id><pub-id pub-id-type="pmid">22843840</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pletzer</surname><given-names>D</given-names></name><name><surname>Hancock</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Is synergy the key to treating high-density infections?</article-title><source>Future Microbiology</source><volume>13</volume><fpage>1629</fpage><lpage>1632</lpage><pub-id pub-id-type="doi">10.2217/fmb-2018-0216</pub-id><pub-id pub-id-type="pmid">30426796</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Srisuknimit</surname><given-names>V</given-names></name><name><surname>Rubino</surname><given-names>F</given-names></name><name><surname>Schaefer</surname><given-names>K</given-names></name><name><surname>Ruiz</surname><given-names>N</given-names></name><name><surname>Walker</surname><given-names>S</given-names></name><name><surname>Kahne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Lipid II overproduction allows direct assay of transpeptidase inhibition by β-lactams</article-title><source>Nature Chemical Biology</source><volume>13</volume><fpage>793</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2388</pub-id><pub-id pub-id-type="pmid">28553948</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radlinski</surname><given-names>L</given-names></name><name><surname>Rowe</surname><given-names>SE</given-names></name><name><surname>Kartchner</surname><given-names>LB</given-names></name><name><surname>Maile</surname><given-names>R</given-names></name><name><surname>Cairns</surname><given-names>BA</given-names></name><name><surname>Vitko</surname><given-names>NP</given-names></name><name><surname>Gode</surname><given-names>CJ</given-names></name><name><surname>Lachiewicz</surname><given-names>AM</given-names></name><name><surname>Wolfgang</surname><given-names>MC</given-names></name><name><surname>Conlon</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Pseudomonas aeruginosa</italic> exoproducts determine antibiotic efficacy against <italic>Staphylococcus aureus</italic></article-title><source>PLOS Biology</source><volume>15</volume><elocation-id>e2003981</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2003981</pub-id><pub-id pub-id-type="pmid">29176757</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radlinski</surname><given-names>LC</given-names></name><name><surname>Rowe</surname><given-names>SE</given-names></name><name><surname>Brzozowski</surname><given-names>R</given-names></name><name><surname>Wilkinson</surname><given-names>AD</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Eswara</surname><given-names>P</given-names></name><name><surname>Conlon</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chemical induction of aminoglycoside uptake overcomes antibiotic tolerance and resistance in <italic>Staphylococcus aureus</italic></article-title><source>Cell Chemical Biology</source><volume>26</volume><fpage>1355</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2019.07.009</pub-id><pub-id pub-id-type="pmid">31402316</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rajagopal</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><chapter-title>Envelope structures of gram-positive bacteria</chapter-title><person-group person-group-type="editor"><name><surname>Bagnoli</surname><given-names>F</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name></person-group><source>In: Protein and Sugar Export and Assembly in Gram-Positive Bacteria</source><publisher-name>Springer International Publishing</publisher-name><fpage>1</fpage><lpage>44</lpage></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichmann</surname><given-names>NT</given-names></name><name><surname>Tavares</surname><given-names>AC</given-names></name><name><surname>Saraiva</surname><given-names>BM</given-names></name><name><surname>Jousselin</surname><given-names>A</given-names></name><name><surname>Reed</surname><given-names>P</given-names></name><name><surname>Pereira</surname><given-names>AR</given-names></name><name><surname>Monteiro</surname><given-names>JM</given-names></name><name><surname>Sobral</surname><given-names>RG</given-names></name><name><surname>VanNieuwenhze</surname><given-names>MS</given-names></name><name><surname>Fernandes</surname><given-names>F</given-names></name><name><surname>Pinho</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SEDS-bpbp pairs direct lateral and septal peptidoglycan synthesis in <italic>Staphylococcus aureus</italic></article-title><source>Nature Microbiology</source><volume>4</volume><fpage>1368</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0437-2</pub-id><pub-id pub-id-type="pmid">31086309</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="1963">1963</year><article-title>The use of lead citrate at high ph as an electron-opaque stain in electron microscopy</article-title><source>The Journal of Cell Biology</source><volume>17</volume><fpage>208</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1083/jcb.17.1.208</pub-id><pub-id pub-id-type="pmid">13986422</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rick</surname><given-names>PD</given-names></name><name><surname>Hubbard</surname><given-names>GL</given-names></name><name><surname>Kitaoka</surname><given-names>M</given-names></name><name><surname>Nagaki</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name><name><surname>Dowd</surname><given-names>S</given-names></name><name><surname>Simplaceanu</surname><given-names>V</given-names></name><name><surname>Ho</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Characterization of the lipid-carrier involved in the synthesis of enterobacterial common antigen (ECA) and identification of a novel phosphoglyceride in a mutant of Salmonella typhimurium defective in ECA synthesis</article-title><source>Glycobiology</source><volume>8</volume><fpage>557</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1093/glycob/8.6.557</pub-id><pub-id pub-id-type="pmid">9592122</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>BL</given-names></name><name><surname>Poot</surname><given-names>M</given-names></name><name><surname>Yue</surname><given-names>ST</given-names></name><name><surname>Millard</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Bacterial viability and antibiotic susceptibility testing with sytox green nucleic acid stain</article-title><source>Applied and Environmental Microbiology</source><volume>63</volume><fpage>2421</fpage><lpage>2431</lpage><pub-id pub-id-type="doi">10.1128/aem.63.6.2421-2431.1997</pub-id><pub-id pub-id-type="pmid">9172364</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>E</given-names></name><name><surname>Keynan</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Vancomycin revisited-60 years later</article-title><source>Frontiers in Public Health</source><volume>2</volume><elocation-id>217</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2014.00217</pub-id><pub-id pub-id-type="pmid">25401098</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeloh</surname><given-names>D</given-names></name><name><surname>Tipmanee</surname><given-names>V</given-names></name><name><surname>Jim</surname><given-names>KK</given-names></name><name><surname>Dekker</surname><given-names>MP</given-names></name><name><surname>Bitter</surname><given-names>W</given-names></name><name><surname>Voravuthikunchai</surname><given-names>SP</given-names></name><name><surname>Wenzel</surname><given-names>M</given-names></name><name><surname>Hamoen</surname><given-names>LW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The novel antibiotic rhodomyrtone traps membrane proteins in vesicles with increased fluidity</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1006876</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006876</pub-id><pub-id pub-id-type="pmid">29451901</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saraiva</surname><given-names>BM</given-names></name><name><surname>Sorg</surname><given-names>M</given-names></name><name><surname>Pereira</surname><given-names>AR</given-names></name><name><surname>Ferreira</surname><given-names>MJ</given-names></name><name><surname>Caulat</surname><given-names>LC</given-names></name><name><surname>Reichmann</surname><given-names>NT</given-names></name><name><surname>Pinho</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reassessment of the distinctive geometry of <italic>Staphylococcus aureus</italic> cell division</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4097</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17940-9</pub-id><pub-id pub-id-type="pmid">32796861</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>JY</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneewind</surname><given-names>O</given-names></name><name><surname>Missiakas</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic manipulation of <italic>Staphylococcus aureus</italic></article-title><source>Current Protocols in Microbiology</source><volume>32</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.1002/9780471729259.mc09c03s32</pub-id><pub-id pub-id-type="pmid">24510849</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Senn</surname><given-names>MM</given-names></name><name><surname>Berger-Bächi</surname><given-names>B</given-names></name><name><surname>Tossi</surname><given-names>A</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name><name><surname>Wiedemann</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-gly5) of <italic>Staphylococcus aureus</italic></article-title><source>Molecular Microbiology</source><volume>53</volume><fpage>675</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2004.04149.x</pub-id><pub-id pub-id-type="pmid">15228543</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>An oldie but a goodie-cell wall biosynthesis as antibiotic target pathway</article-title><source>International Journal of Medical Microbiology</source><volume>300</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2009.10.005</pub-id><pub-id pub-id-type="pmid">20005776</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shurko</surname><given-names>JF</given-names></name><name><surname>Galega</surname><given-names>RS</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evaluation of LL-37 antimicrobial peptide derivatives alone and in combination with vancomycin against <italic>S. aureus</italic></article-title><source>The Journal of Antibiotics</source><volume>71</volume><fpage>971</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1038/s41429-018-0090-7</pub-id><pub-id pub-id-type="pmid">30120393</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sidders</surname><given-names>AE</given-names></name><name><surname>Radlinski</surname><given-names>LC</given-names></name><name><surname>Rowe</surname><given-names>SE</given-names></name><name><surname>Conlon</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2021">2021</year><chapter-title>Stimulating aminoglycoside uptake to kill <italic>Staphylococcus aureus</italic> persisters</chapter-title><person-group person-group-type="editor"><name><surname>Verstraeten</surname><given-names>N</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name></person-group><source>In: Bacterial Persistence: Methods and Protocols</source><publisher-name>Springer US</publisher-name><fpage>223</fpage><lpage>236</lpage></element-citation></ref><ref id="bib86"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Sidders</surname><given-names>AE</given-names></name><name><surname>Kedziora</surname><given-names>KM</given-names></name><name><surname>Arts</surname><given-names>M</given-names></name><name><surname>Daniel</surname><given-names>JM</given-names></name><name><surname>de Benedetti</surname><given-names>S</given-names></name><name><surname>Beam</surname><given-names>JE</given-names></name><name><surname>Bui</surname><given-names>DT</given-names></name><name><surname>Parsons</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Rowe</surname><given-names>SE</given-names></name><name><surname>Conlon</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Analysis of bacteria treated with antimicrobial fatty acids</data-title><version designator="swh:1:rev:b18160031e6dd86bcd14d0dfb144c2ebd09c03b0">swh:1:rev:b18160031e6dd86bcd14d0dfb144c2ebd09c03b0</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:809754cd5a7c5ace0644a2333acb44b6d1ccfe5a;origin=https://github.com/fjorka/bacteria_pa_van_analysis;visit=swh:1:snp:3a384e53243b3929f175e483cf5fe68fc5589444;anchor=swh:1:rev:b18160031e6dd86bcd14d0dfb144c2ebd09c03b0">https://archive.softwareheritage.org/swh:1:dir:809754cd5a7c5ace0644a2333acb44b6d1ccfe5a;origin=https://github.com/fjorka/bacteria_pa_van_analysis;visit=swh:1:snp:3a384e53243b3929f175e483cf5fe68fc5589444;anchor=swh:1:rev:b18160031e6dd86bcd14d0dfb144c2ebd09c03b0</ext-link></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Coffman</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hidden mode of action of glycopeptide antibiotics: inhibition of wall teichoic acid biosynthesis</article-title><source>The Journal of Physical Chemistry. B</source><volume>121</volume><fpage>3925</fpage><lpage>3932</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.7b00324</pub-id><pub-id pub-id-type="pmid">28368603</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skinner</surname><given-names>SO</given-names></name><name><surname>Sepúlveda</surname><given-names>LA</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Golding</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Measuring mRNA copy number in individual <italic>Escherichia coli</italic> cells using single-molecule fluorescent in situ hybridization</article-title><source>Nature Protocols</source><volume>8</volume><fpage>1100</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.066</pub-id><pub-id pub-id-type="pmid">23680982</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A broad-spectrum antibiotic adjuvant reverses multidrug-resistant gram-negative pathogens</article-title><source>Nature Microbiology</source><volume>5</volume><fpage>1040</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0723-z</pub-id><pub-id pub-id-type="pmid">32424338</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>VR</given-names></name><name><surname>Bottomley</surname><given-names>AL</given-names></name><name><surname>Garcia-Lara</surname><given-names>J</given-names></name><name><surname>Kasturiarachchi</surname><given-names>J</given-names></name><name><surname>Foster</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Multiple essential roles for EzrA in cell division of <italic>Staphylococcus aureus</italic></article-title><source>Molecular Microbiology</source><volume>80</volume><fpage>542</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2011.07591.x</pub-id><pub-id pub-id-type="pmid">21401734</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>KJ</given-names></name><name><surname>Strominger</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="1971">1971</year><article-title>Mechanism of action of bacitracin: complexation with metal ion and C 55 -isoprenyl pyrophosphate</article-title><source>PNAS</source><volume>68</volume><fpage>3223</fpage><lpage>3227</lpage><pub-id pub-id-type="doi">10.1073/pnas.68.12.3223</pub-id><pub-id pub-id-type="pmid">4332017</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strahl</surname><given-names>H</given-names></name><name><surname>Bürmann</surname><given-names>F</given-names></name><name><surname>Hamoen</surname><given-names>LW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The actin homologue mreb organizes the bacterial cell membrane</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>3442</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms4442</pub-id><pub-id pub-id-type="pmid">24603761</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stringer</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Michaelos</surname><given-names>M</given-names></name><name><surname>Pachitariu</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cellpose: a generalist algorithm for cellular segmentation</article-title><source>Nature Methods</source><volume>18</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/s41592-020-01018-x</pub-id><pub-id pub-id-type="pmid">33318659</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takigawa</surname><given-names>H</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Kuzukawa</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Imokawa</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Deficient production of hexadecenoic acid in the skin is associated in part with the vulnerability of atopic dermatitis patients to colonization by <italic>Staphylococcus aureus</italic></article-title><source>Dermatology</source><volume>211</volume><fpage>240</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1159/000087018</pub-id><pub-id pub-id-type="pmid">16205069</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tizro</surname><given-names>P</given-names></name><name><surname>Choi</surname><given-names>C</given-names></name><name><surname>Khanlou</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1897">1897</year><article-title>Sample preparation for transmission electron microscopy</article-title><source>Methods in Molecular Biology</source><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-8935-5</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udekwu</surname><given-names>KI</given-names></name><name><surname>Parrish</surname><given-names>N</given-names></name><name><surname>Ankomah</surname><given-names>P</given-names></name><name><surname>Baquero</surname><given-names>F</given-names></name><name><surname>Levin</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Functional relationship between bacterial cell density and the efficacy of antibiotics</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>63</volume><fpage>745</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn554</pub-id><pub-id pub-id-type="pmid">19218572</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uttley</surname><given-names>AH</given-names></name><name><surname>Collins</surname><given-names>CH</given-names></name><name><surname>Naidoo</surname><given-names>J</given-names></name><name><surname>George</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Vancomycin-resistant enterococci</article-title><source>Lancet</source><volume>1</volume><fpage>57</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(88)91037-9</pub-id><pub-id pub-id-type="pmid">2891921</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Bergh</surname><given-names>B</given-names></name><name><surname>Fauvart</surname><given-names>M</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Formation, physiology, ecology, evolution and clinical importance of bacterial persisters</article-title><source>FEMS Microbiology Reviews</source><volume>41</volume><fpage>219</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1093/femsre/fux001</pub-id><pub-id pub-id-type="pmid">28333307</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Walt</surname><given-names>S</given-names></name><name><surname>Schönberger</surname><given-names>JL</given-names></name><name><surname>Nunez-Iglesias</surname><given-names>J</given-names></name><name><surname>Boulogne</surname><given-names>F</given-names></name><name><surname>Warner</surname><given-names>JD</given-names></name><name><surname>Yager</surname><given-names>N</given-names></name><name><surname>Gouillart</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><collab>scikit-image contributors</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Scikit-image: image processing in python</article-title><source>PeerJ</source><volume>2</volume><elocation-id>e453</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.453</pub-id><pub-id pub-id-type="pmid">25024921</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LL</given-names></name><name><surname>Johnson</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Inhibition of listeria monocytogenes by fatty acids and monoglycerides</article-title><source>Applied and Environmental Microbiology</source><volume>58</volume><fpage>624</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1128/aem.58.2.624-629.1992</pub-id><pub-id pub-id-type="pmid">1610184</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weimann</surname><given-names>E</given-names></name><name><surname>Silva</surname><given-names>MBB</given-names></name><name><surname>Murata</surname><given-names>GM</given-names></name><name><surname>Bortolon</surname><given-names>JR</given-names></name><name><surname>Dermargos</surname><given-names>A</given-names></name><name><surname>Curi</surname><given-names>R</given-names></name><name><surname>Hatanaka</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Topical anti-inflammatory activity of palmitoleic acid improves wound healing</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0205338</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0205338</pub-id><pub-id pub-id-type="pmid">30307983</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>M</given-names></name><name><surname>Vischer</surname><given-names>NOE</given-names></name><name><surname>Strahl</surname><given-names>H</given-names></name><name><surname>Hamoen</surname><given-names>LW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Assessing membrane fluidity and visualizing fluid membrane domains in bacteria using fluorescent membrane dyes</article-title><source>Bio-Protocol</source><volume>8</volume><elocation-id>e3063</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.3063</pub-id><pub-id pub-id-type="pmid">34532528</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiedemann</surname><given-names>I</given-names></name><name><surname>Benz</surname><given-names>R</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study</article-title><source>Journal of Bacteriology</source><volume>186</volume><fpage>3259</fpage><lpage>3261</lpage><pub-id pub-id-type="doi">10.1128/JB.186.10.3259-3261.2004</pub-id><pub-id pub-id-type="pmid">15126490</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wille</surname><given-names>JJ</given-names></name><name><surname>Kydonieus</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Palmitoleic acid isomer (C16:1delta6) in human skin sebum is effective against gram-positive bacteria</article-title><source>Skin Pharmacology and Applied Skin Physiology</source><volume>16</volume><fpage>176</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1159/000069757</pub-id><pub-id pub-id-type="pmid">12677098</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasir</surname><given-names>M</given-names></name><name><surname>Dutta</surname><given-names>D</given-names></name><name><surname>Willcox</surname><given-names>MDP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SMode of action of the antimicrobial peptide mel4 is independent of staphyloc occus aureus cell mem brane permeability</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0215703</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0215703</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Matsuo</surname><given-names>M</given-names></name><name><surname>Oogai</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>F</given-names></name><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Sugai</surname><given-names>M</given-names></name><name><surname>Komatsuzawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Bacitracin sensing and resistance in <italic>Staphylococcus aureus</italic></article-title><source>FEMS Microbiology Letters</source><volume>320</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2011.02291.x</pub-id><pub-id pub-id-type="pmid">21517944</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>CJ</given-names></name><name><surname>Yoo</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>TG</given-names></name><name><surname>Cho</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>WG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids</article-title><source>FEBS Letters</source><volume>579</volume><fpage>5157</fpage><lpage>5162</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2005.08.028</pub-id><pub-id pub-id-type="pmid">16146629</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Halladin</surname><given-names>DK</given-names></name><name><surname>Rojas</surname><given-names>ER</given-names></name><name><surname>Koslover</surname><given-names>EF</given-names></name><name><surname>Lee</surname><given-names>TK</given-names></name><name><surname>Huang</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mechanical crack propagation drives millisecond daughter cell separation in staphylococcus aureus</article-title><source>Science</source><volume>348</volume><fpage>574</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1126/science.aaa1511</pub-id><pub-id pub-id-type="pmid">25931560</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zielińska</surname><given-names>A</given-names></name><name><surname>Savietto</surname><given-names>A</given-names></name><name><surname>de Sousa Borges</surname><given-names>A</given-names></name><name><surname>Martinez</surname><given-names>D</given-names></name><name><surname>Berbon</surname><given-names>M</given-names></name><name><surname>Roelofsen</surname><given-names>JR</given-names></name><name><surname>Hartman</surname><given-names>AM</given-names></name><name><surname>de Boer</surname><given-names>R</given-names></name><name><surname>Van der Klei</surname><given-names>IJ</given-names></name><name><surname>Hirsch</surname><given-names>AK</given-names></name><name><surname>Habenstein</surname><given-names>B</given-names></name><name><surname>Bramkamp</surname><given-names>M</given-names></name><name><surname>Scheffers</surname><given-names>D-J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Flotillin-mediated membrane fluidity controls peptidoglycan synthesis and mreb movement</article-title><source>eLife</source><volume>9</volume><elocation-id>e57179</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.57179</pub-id><pub-id pub-id-type="pmid">32662773</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80246.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Helaine</surname><given-names>Sophie</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.05.03.490474" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.03.490474"/></front-stub><body><p>The authors present how unsaturated fatty acids modulate the bactericidal effect of the antibiotic vancomycin. The authors find that palmitoleic acid significantly increases the bactericidal activity of vancomycin and reveal the mechanism responsible. The key findings will be of interest to a broad audience of researchers focused on microbiology, host-pathogen interactions, and antimicrobial development, as well as to clinicians that treat antibiotic-recalcitrant infections.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80246.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Helaine</surname><given-names>Sophie</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Cassat</surname><given-names>Jim</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dq2gs74</institution-id><institution>Vanderbilt University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.03.490474">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.05.03.490474v1.full">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Antibiotic-induced accumulation of lipid II synergizes with antimicrobial fatty acids to eradicate bacterial populations&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Wendy Garrett as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Jim Cassat (Reviewer #1).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission. Please attend to the points listed by the editor, the full reviews are appended below for your information only.</p><p>Essential revisions:</p><p>1. It is unclear if bacteria in other growth phases would be killed by dual PA and Vanc therapy. Please test if bacterial cultures approaching the stationary phase are also effectively killed by UFAs plus Vanc. Results will dictate how much can be concluded about tolerant cells.</p><p>2. The proposed mechanism of UFA/Vanc synergy of accumulation of lipid II and alterations of membrane fluidity is partially demonstrated. Please strengthen these findings with the following experiments:</p><p>– Assess lipid II buildup under treatment conditions employed and thus determine if there is a correlation between the degree of lipid II buildup and the extent of killing. Does the extent of lipid II buildup change over time under vancomycin/bacitracin treatment and if so, does the magnitude and/or rapidity of PA bactericidal effects vary depending on levels of accumulated lipid II at the time of PA addition?</p><p>– Previous work has shown disruption/delocalisation of the divisome via treatment with daptomycin (Muller et al., 2016 PNAS) or zaragozic acid (Garcia-Fernandez et al., 2017 Cell). A floA mutant also has disrupted fluid domains and a crt mutant has a partial phenotype. Overexpression of GpsB antisense mRNA from a multicopy plasmid leads to membrane patches very similar to what is observed here (Eswara et al. <italic>eLife</italic> 38856 2018 Figures 2 and 4). Based on the proposed mechanism here, test whether the effect of the PA treatment is abrogated in some of these conditions.</p><p>– Figure 6 does not show equivalent experiments with fatty acids that do not synergise with vancomycin. Please provide this control.</p><p>– Figure 4 shows that PA causes membrane fluid patches, which may or may not contribute to enhanced killing. Please test whether non-potentiating fatty acids cause patches. If PA specifically causes patches, it would provide stronger support of the model according to which these fluid domains contribute to killing.</p><p>– Lines 280-282: 'Interestingly, these ultrastructural alterations of the cell membrane and septa parallel those reported for lipoglycopeptide treated <italic>S. aureus</italic>', implies that the combination of vancomycin and PA mimics lipoglycopeptide. Please test by combining a lipoglycopeptide with PA, which would presumably not synergise.</p><p>3. Figure 3b would benefit from a positive control to clarify the biological significance of the differences seen. What is the ATP loss with a membrane-damaging agent such as nisin?</p><p>4. Lines 205 and 206 state: 'Vancomycin induces palmitoleic acid incorporation at the septum leading to disruption of functionalized fluid regions'. However, the fluid patches shown in figure 4 are not associated with septa. For example, in Figure 4b, Van +PA(10), none of the patches appear to be near the septa. Please rephrase.</p><p>5. Figure 1b, c. A t-test is inappropriate here because of the multiple comparisons (it is stated that no significant differences were detected unless indicated). Please use a 2-way repeated measures ANOVA. Figure 3b. Were stats done on 9 data points for each condition (3 independent replicates X 3 technical repeats?) as indicated by the figure? This would infer a much greater statistical power than is appropriate and increase the likelihood of P&lt;0.05. Statistical testing should be done with the means of the 3 independent experiments.</p><p>6. Lines 245-247 state: '…dual treated cells had a significant decrease in cell volume after 30 minutes (Figure 4F), suggesting that after prolonged exposure dual treated cells shrink, likely reflecting the leakiness of the membrane'. This set of experiments needs strengthening. Measure cells in each of the growth phases and determine whether this affects cell size. It appears that VAN-treated, and possibly PA-treated, cells have a greater volume than control. This would not fit with the conclusions in the text or figure legend stating that all conductions had p&lt;0.0001 relative to control.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The authors should report the growth phase of bacteria tested in all in vitro experiments. The methods state that overnight cultures were back-diluted at 1:1000, but it is unclear how long these back-diluted cultures were grown. This is important because although persisters are likely present at the high inoculum chosen, other mechanisms of tolerance are more appropriately modeled using bacteria that reach the stationary phase. If the experiments were conducted with exponential phase bacteria, it would improve the manuscript and the interpretation of the efficacy of dual therapy to conduct new experiments with stationary phase bacteria.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The manuscript by Sidders et al., presents the interesting finding that palmitic acid selectively potentiates the vancomycin-mediated killing of <italic>S. aureus</italic>. This is an Interesting observation and the authors attempt to elucidate the underlying mechanism. However, the work lacks some important controls and requires better statistical analysis.</p><p>Specific points:</p><p>1. Figure 1b, c. A t-test is inappropriate here as you have to account for multiple comparisons, even if you don't make them (the more things you measure, the greater the likelihood of getting spurious significance and so you need to account for multiple data points). You should use a 2-way repeated measures ANOVA.</p><p>2. Figure 1. The legend is unclear. For b and c, the legend states the test was done at 6h, but it's clearly done at 22 h for panel c. Further, the legend states no significant difference unless indicated but it's not clear if that means for panel a or all graphs? For b and c, I would suggest indicating points that significantly differ from control.</p><p>3. The legend for figure 3 states: 'Dual treatment impacts membrane permeability but not energetics' but there are no statistical tests shown to support this for membrane permeability and the text states '…some depolarization was observed, however, this was negligible when compared to gramicidin, the pore-forming positive control…' (lines 182-183). Therefore, it's not clear whether the authors believe that significant impacts on the membrane are occurring.</p><p>4. Figure 3b. Were stats done on 9 data points for each condition (3 independent replicates X 3 technical repeats?) as indicated by the figure? This would infer a much greater statistical power than is appropriate and increase the likelihood of P&lt;0.05. Statistical testing should be done with the means of the 3 independent experiments.</p><p>5. Figure 3b would benefit from a positive control to clarify the biological significance of the differences seen. What is the ATP loss with a membrane-damaging agent such as nisin?</p><p>6. Lines 205 and 206 state: 'Vancomycin induces palmitoleic acid incorporation at the septum leading to disruption of functionalized fluid regions'. However, the fluid patches shown in figure 4 are not associated with septa. For example, in Figure 4b, Van +PA(10), none of the patches appear to be near the septa. Furthermore, there is no evidence that functional domains are disrupted at this point – evidence comes later in the manuscript via mis-localisation of cell wall machinery as observed using gfp-tagged enzyme (but see point 12).</p><p>7. Figure 4 shows that PA causes membrane fluid patches, which may or may not contribute to enhanced killing. However, there is no examination of whether non-potentiating fatty acids cause patches. If it can be shown that PA specifically causes patches then that would provide some evidence that these fluid domains contribute to killing. This would seem to be a critically important experiment.</p><p>8. Figure 4d: How many independent experiments were done here? Please show SD for data. Were any statistical tests done?</p><p>9. Lines 245-247 state: '…dual treated cells had a significant decrease in cell volume after 30 minutes (Figure 4F), suggesting that after prolonged exposure dual treated cells shrink, likely reflecting the leakiness of the membrane'. This statement lacks any supporting evidence/citations and it's much more likely that any effects on size are governed by the cell wall rather than the membrane since this is the outer-most structure, perhaps reflective of the observed shift in the proportion of cells in the growth phase 3. A useful control here would be to measure cells in each of the growth phases and determine whether this affects cell size.</p><p>10. Lines 280-282: 'Interestingly, these ultrastructural alterations of the cell membrane and septa parallel those reported for lipoglycopeptide treated <italic>S. aureus</italic>', presumably suggesting that the combination of vancomycin and PA mimic lipoglycopeptide. This could be tested by combining a lipoglycopeptide with PA, which would presumably not synergise.</p><p>11. Figure 6 does not show equivalent experiments with fatty acids that do not synergise with vancomycin. This is another critical experiment if mis-localisation of cell wall machinery is to be considered to contribute to the phenotype.</p><p>12. The susceptibility of strains to vancomycin is unclear. How much less susceptible are the VISA/VRSA isolates relative to the strain used initially? MIC values should be provided.</p><p>13. It's not clear what the dose-response profile for PA looks like. Would physiological serum levels of PA enhance vancomycin-mediated killing? It would be useful for the authors to comment on how host-derived PA might modulate vancomycin activity in vivo.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>There is a lot of data showing that the combination causes effects that other peptidoglycan-targeting treatments do not, but formulating a specific mechanism could be aided by showing what other peptidoglycan-targeting treatments with known mechanisms do that this one does not, in order to eliminate those alternative mechanistic hypotheses.</p><p>Likewise, some ways to specifically enhance or lessen the effectiveness of the combination treatment based on the proposed mechanism would be persuasive to validate the mechanistic hypothesis, conceptually similar to how mutations that are consistent with a proposed mechanism in the effect they have on antibiotic efficacy help validate a protein as a target of an antibiotic.</p><p>If authors believe that the mechanism of the vancomycin-palmitoleic acid combination is conserved across all the species they investigate, then the larger <italic>B. subtilis</italic> cells might offer ways to probe the mechanism that the small S. aureus does not.</p><p>It seems that in several of the phenotypes that the authors monitor, additional insights could be gained by pretreating cells with one of the agents for varying lengths of time before adding another, to more precisely ascertain their individual contributions to the combined effect.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80246.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions</p><p>1. It is unclear if bacteria in other growth phases would be killed by dual PA and Vanc therapy. Please test if bacterial cultures approaching the stationary phase are also effectively killed by UFAs plus Vanc. Results will dictate how much can be concluded about tolerant cells.</p></disp-quote><p>We thank the reviewer for this suggestion. In the revised version of the manuscript, we have clarified the text in our methods section to indicate the growth phase and the length of time that the cultures are grown prior to antibiotic addition. We specifically utilized bacterial populations approaching stationary phase in all experiments in this manuscript, as indicated by the minimal increase in bacterial density from the time of challenge (T0) to the final time point evaluated (typically T6) (Figure 1B,C). To better evaluate tolerant populations, we chemically induced tolerance using arsenate to reduce ATP levels (Conlon et al., 2016) or CCCP which collapses the proton motive force. We found that palmitoleic acid still potentiates vancomycin killing against these tolerant populations of <italic>S. aureus</italic> (figure 1—figure supplement 3).</p><disp-quote content-type="editor-comment"><p>2. The proposed mechanism of UFA/Vanc synergy of accumulation of lipid II and alterations of membrane fluidity is partially demonstrated. Please strengthen these findings with the following experiments:</p><p>– Assess lipid II buildup under treatment conditions employed and thus determine if there is a correlation between the degree of lipid II buildup and the extent of killing. Does the extent of lipid II buildup change over time under vancomycin/bacitracin treatment and if so, does the magnitude and/or rapidity of PA bactericidal effects vary depending on levels of accumulated lipid II at the time of PA addition?</p></disp-quote><p>We thank the reviewers for this critical suggestion. As these experiments are specialized, we formed a collaboration with Dr. Tanja Schneider’s group to measure membrane-bound cell wall intermediates following treatment with palmitoleic acid and vancomycin. Indeed, these assays showed that lipid II accumulates, within 30 minutes, in dual treated conditions, but unexpectedly, palmitoleic acid also led to the accumulation of the lipid anchor, bactoprenol (Figure 3). This is an important addition and we have revised our manuscript accordingly and now describe how the combined accumulation of bactoprenol, lipid II, and the insertion of palmitoleic acid into the membrane is driving RIF formation, protein delocalization, and cell death. We discuss these findings in lines 199-216 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>– Previous work has shown disruption/delocalisation of the divisome via treatment with daptomycin (Muller et al., 2016 PNAS) or zaragozic acid (Garcia-Fernandez et al., 2017 Cell). A floA mutant also has disrupted fluid domains and a crt mutant has a partial phenotype. Overexpression of GpsB antisense mRNA from a multicopy plasmid leads to membrane patches very similar to what is observed here (Eswara et al. eLife 38856 2018 Figures2 and 4). Based on the proposed mechanism here, test whether the effect of the PA treatment is abrogated in some of these conditions.</p></disp-quote><p>We appreciate the reviewers suggestions to evaluate conditions that have been linked to similar phenotypes as those observed in our study. Palmitoleic acid does not synergize with daptomycin (Figure 4 —figure supplement 5A), presumably because it is already a potent bactericidal agent that leads to RIF formation on its own. We also evaluated <italic>floA</italic>::Tn and <italic>crtM</italic>::Tn JE2 strains from the Nebraska Transposon Mutant Library. Interestingly, neither strain abrogated the synergy between palmitoleic acid and vancomycin (Figure 4 —figure supplement 5B-D). A recent study in <italic>B. subtilis</italic> showed that a <italic>floAT</italic> mutant increased the rigidity of the membrane overall, but local fluidity at the septum remained increased due to the presence of lipid II which innately disturbs membrane packing (Zielinska et al. 2020). It is possible that we do not see an impact on antibiotic susceptibility because the absence of flotillins does not impact fluidity at the septum. Furthermore, we confirmed that flotillins were not involved by pre-treating <italic>S. aureus</italic> with zaragozic acid, a statin that disrupts flotillin rafts, which had no impact on synergy (Figure 4 —figure supplement 5E). We have discussed these data in lines 287-301 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>– Figure 6 does not show equivalent experiments with fatty acids that do not synergise with vancomycin. Please provide this control.</p><p>– Figure 4 shows that PA causes membrane fluid patches, which may or may not contribute to enhanced killing. Please test whether non-potentiating fatty acids cause patches. If PA specifically causes patches, it would provide stronger support of the model according to which these fluid domains contribute to killing.</p></disp-quote><p>We thank the reviewer for these suggestions. Supplements for figure 4 and 7 illustrate that the distinct phenotypes we observe with the palmitoleic acid-vancomycin combination are not present in <italic>S. aureus</italic> treated with a representative non-potentiating CMAA combined with vancomycin nor when cells are treated with a cell wall acting antibiotic that does not synergize with palmitoleic acid.</p><disp-quote content-type="editor-comment"><p>– Lines 280-282: 'Interestingly, these ultrastructural alterations of the cell membrane and septa parallel those reported for lipoglycopeptide treated <italic>S. aureus</italic>', implies that the combination of vancomycin and PA mimics lipoglycopeptide. Please test by combining a lipoglycopeptide with PA, which would presumably not synergise.</p></disp-quote><p>We are grateful for this reviewers suggestion and as expected oritavancin did not impact synergy between palmitoleic acid and vancomycin (figure 6 —figure supplement 1).</p><disp-quote content-type="editor-comment"><p>3. Figure 3b would benefit from a positive control to clarify the biological significance of the differences seen. What is the ATP loss with a membrane-damaging agent such as nisin?</p></disp-quote><p>We have since reevaluated our previous membrane permeability assays. Previously we used 7 μg/ml palmitoleic acid as that was the highest concentration, we could use without causing quenching the membrane potential dye DiSC<sub>3</sub>. However, to evaluate permeability more accurately we have since increased palmitoleic acid to the concentration used throughout the manuscript (11 μg/ml) and used SYTOX green which is not quenched at these concentrations. We have also included nisin as a positive control. We find that while palmitoleic acid alone increases ATP leakage, dual treated cells have a significant increase in small molecule leakage when compared to monotherapy, similar to nisin. However, using SYTOX green, we find that leakage is not due to pore formation as uptake of SYTOX green only occurred in nisin treated conditions. These data are presented in figure 5 and discussed in lines 333-353 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>4. Lines 205 and 206 state: 'Vancomycin induces palmitoleic acid incorporation at the septum leading to disruption of functionalized fluid regions'. However, the fluid patches shown in figure 4 are not associated with septa. For example, in Figure 4b, Van +PA(10), none of the patches appear to be near the septa. Please rephrase.</p></disp-quote><p>We appreciate the reviewer identifying this error, we have since rephrased that section in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>5. Figure 1b, c. A t-test is inappropriate here because of the multiple comparisons (it is stated that no significant differences were detected unless indicated). Please use a 2-way repeated measures ANOVA. Figure 3b. Were stats done on 9 data points for each condition (3 independent replicates X 3 technical repeats?) as indicated by the figure? This would infer a much greater statistical power than is appropriate and increase the likelihood of P&lt;0.05. Statistical testing should be done with the means of the 3 independent experiments.</p></disp-quote><p>We appreciate the reviewers identification of improper statistical analysis in our manuscript. We have since completed a two-way repeated measures ANOVA on the data in figure 1B,C and have clarified the figure legend (lines 132-135).</p><p>The data that was previously labeled as Figure 3B has now been repeated with different conditions and labeled as Figure 5A and we have performed one-way ANOVA with the means of the 2 independent experiments (lines 362-365). The methods and figure legend have been revised for clarity.</p><disp-quote content-type="editor-comment"><p>6. Lines 245-247 state: '…dual treated cells had a significant decrease in cell volume after 30 minutes (Figure 4F), suggesting that after prolonged exposure dual treated cells shrink, likely reflecting the leakiness of the membrane'. This set of experiments needs strengthening. Measure cells in each of the growth phases and determine whether this affects cell size. It appears that VAN-treated, and possibly PA-treated, cells have a greater volume than control. This would not fit with the conclusions in the text or figure legend stating that all conductions had p&lt;0.0001 relative to control.</p></disp-quote><p>We thank the reviewer for their recommendation, we have since added supplement graphs of cell volume for each treatment condition and time point based on the cell phase (figure 4 —figure supplement 3 and figure supplement 4). These data illustrate that after 10 minutes, vancomycin monotherapy led to cells in phase 1 and 2 to yield a significant increase in cell volume, which is well reported in the literature (Salamaga et al. 2021). In comparison, palmitoleic acid monotherapy only resulted an increased cell volume for cells in phase 1. After 30 minutes of vancomycin or palmitoleic acid monotherapy, cells in both phase 1 and phase 2 had a significant increase in cell volume compared to the control cells. Interestingly, while palmitoleic acid monotherapy did not yield a significant difference in cell volume in phase 3 cells, vancomycin monotherapy resulted in a decrease in cell volume. These new data are now discussed in line (274-279) of the revised manuscript.</p></body></sub-article></article>